PMID,Multiple Answer,time_usage
18715920,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro experiments and does not mention specific years for sample collection.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: To delineate the effect of resistance mutations on viral susceptibility to integrase inhibitors, in vitro resistance selections with raltegravir and with MK-2048, an integrase inhibitor with a second-generation-like resistance profile, were performed.

Rationale: The paper mentions to delineate the effect of resistations mutations on viral susceptibility to integrase inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro experiments, which doesn't report new sequences, and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not cloned from clinical samples.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Site-directed mutants (SDMs) of IN coding sequences were constructed in the pUC19-5′HXB2D vector (XbaI–SalI fragment of pHXB2D), containing the HIV-1 clone HXB2D IN coding sequence, by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) and high-performance liquid chromatography-purified primers (Genset Oligos, La Jolla, CA).

Rationale: The paper focuses on the integrase gene (IN) of HIV-1, and mentioned that SDM of IN were confiredm by sequencing.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Plasmid sequences were confirmed by dideoxyribose sequencing. PCR products were genotyped by automated population-based full-sequence analysis (ABI PRISM BigDye Terminator cycle sequencing; Applied Biosystems, Foster City, CA).

Rationale: The paper mentions the use of dideoxyribose sequencing, and ABI PRISM BigDye Terminator cycle sequencing which means the study was using sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.

Rationale: The paper mentioned in vitro reistance selection, and all sequences were generated using site-directed mutation technology, which means the sequence were not from clinical samples.

Answer: Not reported
""""""",98
19104010,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The IN strand transfer assay has been previously described (46). Briefly, biotinylated donor DNA was bound to streptavidin-coated plates. Unbound donor DNA was removed by washing, and IN was then added to each well to allow 3′ processing of the donor DNA end for 30 min. Digoxigenin-tagged target DNA was next added to each well, and the 3′-end-joining reaction was allowed to proceed for 30 min. The wells were washed to remove unjoined target DNA, and the chemiluminescence signal was detected following addition of horseradish peroxidase-conjugated antidigoxigenin antibody. Test compounds were added immediately before the target DNA.""

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to various compounds using a strand transfer assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The IN gene from 24 individual plasmid clones was sequenced using the BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA).""

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, and mentioned that IN gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sequencing reactions were analyzed by the ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster City, CA).""

Rationale: The paper mentions the use of ABI Prism 3100 genetic analyzer, which means the study was using sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""",81
21115794,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Phenotypic analyses of viral isolates and drug-resistant molecular clones.\nThe drug sensitivities of the viruses isolated during the passage study and the drug-resistant molecular clones were assessed by a reporter assay with HeLa-CD4 cells, as described previously (24, 25). Briefly, viral isolates from the passage study were expanded in fresh M8166 cells. The test compounds were diluted to appropriate concentrations with culture medium, and HeLa-CD4 cell suspensions (2.5 × 104 cells/well) were dispensed into each plate. The effective drug concentration reducing HIV-1 replication to 50% (EC50) was calculated.""

Rationale: The paper includes detailed phenotypic analyses of viral isolates and drug-resistant molecular clones, with the mention of calculating EC50.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The sequencing of the products was entrusted to the Operon Biotechnologies sequencing service (Tokyo, Japan). The sequence of the IN region derived from isolated viruses was compared with that of the wild-type NL432 IN region, and amino acid substitutions were identified The recombinant HIV-1 molecular clones were constructed as follows. The XbaI-EcoR I fragment from pNL-IN301 (pNL432 with the XbaI site inserted into the 5′ end of the IN region) was cloned at the XbaI-EcoR I site of cloning vector pUC18""

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, as it discusses mutations and resistance related to integrase strand transfer inhibitors (INSTIs).

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""",91
23749954,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper describes the resistance selection experiments conducted with tenofovir alafenamide (TAF) and tenofovir (TFV). The study used a dose escalation method and analyzed genotypic and phenotypic changes in the virus over time.

Rationale: The paper describes the resistance selection experiments conducted with tenofovir alafenamide (TAF) and tenofovir (TFV). The study used a dose escalation method and analyzed genotypic and phenotypic changes in the virus over time.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It focuses on the resistance profiles and phenotypic analyses without mentioning specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries from which the sequenced samples were obtained. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not mention the specific countries from which the sequenced samples were obtained. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether the samples were cloned prior to sequencing. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Rationale: The paper does not mention whether the samples were cloned prior to sequencing. It focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the method used for sequencing.

Rationale: The paper does not specify the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the type of samples sequenced.

Rationale: The paper does not specify the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not mention whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients were part of a clinical trial.

Rationale: The paper does not mention whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention whether the sequences were from individuals who had previously received ARV drugs.

Rationale: The paper does not mention whether the sequences were from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",96
24227862,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention the use of patient samples for obtaining HIV sequences. It focus on the integrase strand transfer activity and susceptibility to DTG both biochemically and in tissue culture.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focus on the integrase strand transfer activity and susceptibility to DTG both biochemically and in tissue culture.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information on the years from which sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the timeline of sample collection.

Rationale: The paper does not provide any information on the years from which sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the timeline of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Rationale: The paper mentioned the study was about integrase transfer activity and susceptiblity, no sequences samples were from individuals.

Answer: Not reported
""""""",96
25637519,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Phenotypic analysis of the susceptibility of virus variants to RT inhibitors: (a) nevirapine (NVP), (b) efavirenz (EFV), (c) etravirine (ETR), (d) rilpivirine (RPV) and (e) NRTIs (ZDV, zidovudine; ABC, abacavir sulphate; 3TC, lamivudine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate).""

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to various RT inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained. It mentions the study's timeline and publication dates but does not specify the years of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The models of HIV-1 CRF08_BC RT (1--560 amino acids) (WT containing D404 and mutant containing N404) were built by homology modelling with HIV-1 RT, nevirapine and RNA/DNA hybrid crystal structure 4PUO using the server SWISS-MODEL with default parameters.""

Rationale: The paper focuses on the reverse transcriptase (RT) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention the virological outcomes of the individuals from whom the sequences were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals from whom the sequences were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals from whom the sequences were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals from whom the sequences were obtained. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""",83
26246578,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 subtype B IN polymorphism frequencies (%) were evaluated using specimens from HIV-1-infected patients at the National Hospital Organization Nagoya Medical Center, Japan ( Fig. 1 ). A total of 600 IN sequences were analyzed; 458 samples were obtained from antiretroviral therapy (ART)-naïve individuals, and 142 samples were obtained from ART-experienced individuals, including patients carrying the Y143C ( *n* = 1), Q148H/R ( *n* = 8) or N155H ( *n* = 12) mutation.

Rationale: The paper mentions the use of patient samples for obtaining HIV sequences, specifically for evaluating HIV-1 subtype B IN polymorphism frequencies.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes data on HIV-1 susceptibility to DTG, RAL, and EVG in tissue culture, as well as the determination of the 50% inhibitory concentration (IC50) for these drugs.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG), raltegravir (RAL), and elvitegravir (EVG) using tissue culture assays.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 600 IN sequences were analyzed; 458 samples were obtained from antiretroviral therapy (ART)-naïve individuals, and 142 samples were obtained from ART-experienced individuals, including patients carrying the Y143C ( *n* = 1), Q148H/R ( *n* = 8) or N155H ( *n* = 12) mutation.

Rationale: The paper states that a total of 600 IN sequences were analyzed, with 458 samples obtained from ART-naïve individuals and 142 samples from ART-experienced individuals.

Answer: 600
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: HIV-1 subtype B IN polymorphism frequencies (%) were evaluated using specimens from HIV-1-infected patients at the National Hospital Organization Nagoya Medical Center, Japan ( Fig. 1 ).

Rationale: The paper mentions that the HIV-1 subtype B IN polymorphism frequencies were evaluated using specimens from HIV-1-infected patients at the National Hospital Organization Nagoya Medical Center, Japan.

Answer: Japan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide any information on the years from which sequenced samples were obtained.

Rationale: The paper does not provide any information on the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, discussing various polymorphisms and resistance-associated mutations within this gene.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, specifically examining mutations and their effects on drug resistance and enzyme activity.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that near full-length HIV-1 genome fragments were amplified and sequenced using the MiSeq platform, which is an Illumina sequencing technology.

Rationale: The paper mentions that near full-length HIV-1 genome fragments were amplified and sequenced using the MiSeq platform, which is an Illumina sequencing technology.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that INSTI resistance-associated mutations were analyzed using viral RNA from plasma.

Rationale: The paper mentions that INSTI resistance-associated mutations were analyzed using viral RNA from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes two cases of virological failure during raltegravir-based therapy, indicating that sequences were obtained from individuals experiencing virological failure.

Rationale: The paper describes two cases of virological failure during raltegravir-based therapy, indicating that sequences were obtained from individuals experiencing virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 142 samples were obtained from ART-experienced individuals, indicating that sequences were obtained from individuals who had previously received antiretroviral drugs.

Rationale: The paper mentions that 142 samples were obtained from ART-experienced individuals, indicating that sequences were obtained from individuals who had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions various antiretroviral drugs that belong to NRTI Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC), NNRTI: Efavirenz (EFV), CCR5 antagonist Maraviroc (MVC), INST: Raltegravir (RAL).

Rationale: The paper mentions various antiretroviral drugs that belong to different classes, including NRTI, NNRTI, INSTI, and CCR5 antagonist.

Answer: NRTI, NNRTI, INSTI, CCR5 antagonist
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper specifically mentions drugs as part of the treatment regimens received by two cases, Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC).

Rationale: The paper specifically mentions drugs as part of the treatment regimens received by two cases.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV), Maraviroc (MVC), Raltegravir (RAL), Emtricitabine (FTC)
""""""",112
26311878,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes data on HIV-1 susceptibility to DTG, RAL, and EVG in tissue culture, as well as the determination of the 50% inhibitory concentration (IC50) for these drugs.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG), raltegravir (RAL), and elvitegravir (EVG) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing. It focuses on laboratory-based studies and does not mention the use of patient samples.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the use of patient samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained. It focuses on laboratory-based studies and does not mention the use of patient samples.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, discussing various mutations and their effects on drug resistance and viral fitness.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of clinical specimens that were sequenced. The paper mentions that the study is about tissue culture selection.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper mentions that the study is about tissue culture selection, samples were not from patients infected HIV.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper mentions the SAILING clinical trial, but it's not about this study. The paper mentions that the study is about tissue culture selection.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper mentions that the study is about tissue culture selection, the samples it not from patients infected HIV.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper mentions that the study is about tissue culture selection, the samples it not from patients infected HIV.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper mentions that the study is about tissue culture selection, the samples it not from patients infected HIV.

Answer: Not reported
""""""",73
26559830,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention that the study involved HIV sequences from patient samples. It focuses on the protease inhibitors (PI) and their activity against wild-type and mutant HIV-2 strains.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The susceptibilities of each wild-type or mutant HIV-2 molecular clone were determined using a single-cycle assay as described previously (14).""

Rationale: The paper reports in vitro drug susceptibility data for various protease inhibitors (PI) against wild-type and mutant HIV-2 strains.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",57
27009474,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014. His CD4 count at the time of diagnosis was 405 cells/mm3 and his plasma HIV-1 RNA level was 3,980 copies/ml. A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper discusses the analysis of a patient's HIV-1 seroconversion and the results of a baseline genotypic resistance test, indicating that HIV sequences were reported from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: Q148N ± G140S was associated with 2.4- to 4.5-fold reduced susceptibility to elvitegravir but not to raltegravir or dolutegravir (Table 1). This level of INSTI resistance was lower than that observed with Q148H alone (19-fold reduced raltegravir susceptibility and 5.5-fold reduced elvitegravir susceptibility) or Q148H+G140S (>150-fold reduced susceptibility to raltegravir and elvitegravir and 3.4-fold reduced dolutegravir susceptibility).

Rationale: The paper includes data on the effects of specific mutations on drug susceptibility, as shown by the phenotypic susceptibility testing using the PhenoSense assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper explicitly states that the sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Answer: KU761565
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper focuses on a single patient case, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper does not specify the country from which the sequenced sample was obtained, but it mentions that the patient is Hispanic.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.

Rationale: The paper mentions that the patient underwent HIV-1 seroconversion in August 2014.

Answer: 2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper mentions the sequencing and finding of drug resistance mutations on protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper specifies that plasma samples were analyzed, indicating that this was the clinical specimen type used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patient was part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper details the patient's treatment history of antiretroviral drug treatments.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper lists various antiretroviral drugs that the patient received over the years, which fall into the specified drug classes: NRTI (Nucleoside Reverse Transcriptase Inhibitor), including Lamivudine (3TC), Stavudine (D4T), Didanosine (DDI), Emtricitabine (FTC), Tenofovir (TFV); NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor), including Nevirapine (NVP); PI (Protease Inhibitor), including Lopinavir (LPV), Indinavir (IDV); INSTI (Integrase Inhibitor), including Dolutegravir (DTG)

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D that were interpreted as causing intermediate resistance to zidovudine and low-level resistance to tenofovir; the non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistance mutations K101P and K103S that were interpreted as causing high-level resistance to each of the NNRTIs; and the protease inhibitor-resistance mutations D30N, L33F, I54V, N88D, and L90M that were interpreted as causing intermediate or high-level resistance to each of the PIs except darunavir.

Rationale: The paper lists specific drugs that were part of the patient's treatment regimen, confirming the drugs received prior to sequencing.

Answer: Zidovudine (AZT), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Indinavir (IDV), Dolutegravir (DTG)
""""""",150
27124362,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention obtaining HIV sequences from patient samples. It focuses on in vitro resistance selection studies using HIV-1 subtype A, B, and C viruses in cell culture systems.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the fold change of DOR-resistant isolates, it also mentions the mutant viruses in the clinical trial were tested for susceptibility to DOR, which indicates in vitro susceptibliity data were reported.

Rationale: The paper mentions the fold change of DOR-resistant isolates, it also mentions the mutant viruses in the clinical trial were tested for susceptibility to DOR, which indicates in vitro susceptibliity data were reported.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not mention any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any specific number of individuals from whom samples were obtained.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention whether the patients in the study were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention whether the individuals in the study had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",60
28559249,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen.

Rationale: The paper reports HIV sequences from patient samples, specifically from seven heavily pretreated HIV-2-infected patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports in vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2.

Rationale: The paper reports in vitro drug susceptibility data for dolutegravir in both HIV-1 and HIV-2 strains.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients.

Rationale: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients.

Answer: 7
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide specific information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Rationale: The paper does not provide specific information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the complete integrase gene was amplified by population-based sequencing from plasma samples.

Rationale: The paper mentions that the complete integrase gene was amplified by population-based sequencing from plasma samples.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the complete integrase gene was amplified by population-based sequencing from plasma samples.

Rationale: The paper mentions that the complete integrase gene was amplified by population-based sequencing from plasma samples.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were collected and used for sequencing.

Rationale: The paper mentions that plasma samples were collected and used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen.

Rationale: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients exhibiting virological failure while receiving a salvage raltegravir-containing regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients.

Rationale: The paper mentions that the study involved seven heavily pretreated HIV-2-infected patients.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that all patients received darunavir boosted with ritonavir, and the nucleoside reverse transcriptase inhibitors (NRTI) lamivudine (or emtricitabine), abacavir, tenofovir, and zidovudine were received by six, three, four, and one patient, respectively.

Rationale: The paper mentions that all patients received darunavir boosted with ritonavir, and the nucleoside reverse transcriptase inhibitors (NRTI) lamivudine (or emtricitabine), abacavir, tenofovir, and zidovudine were received by six, three, four, and one patient, respectively.

Answer: NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that all patients received darunavir boosted with ritonavir, and the nucleoside reverse transcriptase inhibitors (NRTI) lamivudine (or emtricitabine), abacavir, tenofovir, and zidovudine were received by six, three, four, and one patient, respectively.

Rationale: The paper mentions that all patients received darunavir boosted with ritonavir, and the nucleoside reverse transcriptase inhibitors (NRTI) lamivudine (or emtricitabine), abacavir, tenofovir, and zidovudine were received by six, three, four, and one patient, respectively.

Answer: Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Tenofovir (TDF), Zidovudine (AZT), Darunavir (DRV), Raltegravir (RAL)
""""""",94
29373677,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the case of a patient treated with dolutegravir monotherapy and reports the identification of N155H, K156N, K211R, and E212T mutations in the patient's HIV-1 integrase gene.

Rationale: The paper mentions that the patient's HIV-1 integrase gene was sequenced, and specific mutations were identified. This indicates that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports the results of cell-free reactions and HeLa-P4 cell infections in the presence of increasing concentrations of raltegravir and dolutegravir.

Rationale: The paper describes the use of in vitro assays to determine the susceptibility of HIV-1 isolates to raltegravir and dolutegravir. This indicates that the study reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database. This indicates that the sequences are not publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention the submission of sequences to GenBank or any other public database. This indicates that the sequences are not publicly available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper discusses the case of a single patient treated with dolutegravir monotherapy.

Rationale: The paper focuses on a single patient and does not mention the sequencing of samples from multiple individuals.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the country of origin for the sequenced samples.

Rationale: The paper does not provide information about the country where the patient was from or where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient received antiretroviral treatment from 2008 to 2015.

Rationale: The paper provides a timeline of the patient's treatment but does not specify the exact years when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention the cloning of samples prior to sequencing.

Rationale: The paper does not provide information about the sequencing method used or whether samples were cloned before sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the sequencing of the HIV-1 integrase gene.

Rationale: The paper mentions the sequencing of the HIV-1 integrase gene and the identification of specific mutations within this gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not provide information about the sequencing method used to analyze the HIV-1 integrase gene.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions the sequencing of plasma RNA and DNA from PBMCs.

Rationale: The paper discusses the sequencing of plasma RNA and DNA from PBMCs to identify mutations in the HIV-1 integrase gene.

Answer: Plasma, PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the case of a patient who experienced virological failure on dolutegravir monotherapy.

Rationale: The paper focuses on a patient who experienced treatment failure and reports the identification of mutations in the HIV-1 integrase gene.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper discusses the case of a single patient and does not provide information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the case of a patient who had previously received antiretroviral treatment.

Rationale: The paper mentions that the patient had received antiretroviral treatment from 2008 to 2015.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received INSTIs (integrase inhibitors) and other antiretroviral drugs.

Rationale: The paper discusses the patient's treatment history and mentions the use of INSTIs and other antiretroviral drugs.

Answer: INSTI, other ARV targets
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had received raltegravir and dolutegravir.

Rationale: The paper discusses the patient's treatment history and mentions the use of raltegravir and dolutegravir.

Answer: Raltegravir, Dolutegravir
""""""",84
30053052,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports HIV sequences from patient samples, specifically from therapy-naive and treatment-failure patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that ""DSA was performed on three resistant viruses from treatment-failure patients, one G190A-containing strain from a treatment-naive individual, and seven NNRTI-resistant viruses obtained from the NIH AIDS Reagent Program.""

Rationale: The paper reports in vitro drug susceptibility data, specifically for EFdA and other RTIs against a panel of chimeric viruses.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: There is no evidence to suggest that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: There is no evidence to suggest that the sequences were deposited in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports that samples were obtained from 42 therapy-naive and 9 treatment-failure patients.

Answer: 51
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports that the samples were obtained from Sweden.

Answer: Sweden
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention specific years for when the sequenced samples were obtained.

Rationale: There is no evidence to suggest that the samples were obtained during a specific time period.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: There is no evidence to suggest that the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""The gag-pol fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid following digestion with BssHII and SalI (New England Biolabs, USA) and ligation using T4 DNA ligase (New England Biolabs), as described by us previously.""

Rationale: The paper reports that the gag-pol fragment was sequenced.

Answer: gag-pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""The DSA was performed by determining the extent to which EFdA, nevirapine, efavirenz, etravirine, rilpivirine and tenofovir alafenamide inhibited the replication of the reference virus (NL43) and the 24 treatment-naive patient-derived chimeric viruses (HIV-1B, 6; HIV-1C, 14; HIV-1A-like, 4).""

Rationale: The paper reports that the DSA was performed using a phenotypic assay.

Answer: Phenotypic assay
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: There is no evidence to suggest that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden.""

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes received by individuals in the study before sample sequencing.

Rationale: There is no evidence to suggest that specific drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Rationale: There is no evidence to suggest that specific drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",99
30803972,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial. the study focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial. the study focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Answer: Not reported
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports in vitro drug susceptibility data for bictegravir in both HIV-1 and HIV-2 strains. The study employs single-cycle assays to compare the sensitivity of wild-type and INSTI-resistant strains of HIV-1 and HIV-2 to bictegravir, demonstrating comparable EC50 values across different strains.

Rationale: The paper reports in vitro drug susceptibility data for bictegravir in both HIV-1 and HIV-2 strains. The study employs single-cycle assays to compare the sensitivity of wild-type and INSTI-resistant strains of HIV-1 and HIV-2 to bictegravir, demonstrating comparable EC50 values across different strains.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention the number of individuals from whom samples were obtained for HIV sequencing. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the number of individuals involved.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the origin of the samples used in the study.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not mention the specific time frame for sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the sequencing methods used.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase gene of HIV-1 and HIV-2, examining the effects of various integrase mutations on the susceptibility to bictegravir. The study involves site-directed mutagenesis of the integrase gene to assess resistance profiles.

Rationale: The paper focuses on the integrase gene of HIV-1 and HIV-2, examining the effects of various integrase mutations on the susceptibility to bictegravir. The study involves site-directed mutagenesis of the integrase gene to assess resistance profiles.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the method used for sequencing the HIV isolates. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the sequencing methods used.

Rationale: The paper does not specify the method used for sequencing the HIV isolates. The focus is on the in vitro activity of bictegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about the sequencing methods used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention what clinical specimens were sequences, although PBMC was mentioned it's in the introduction part.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentioned the individuals were INSTI naïve, but not mentioned the treatment history.

Rationale: The paper mentioned the individuals were INSTI naïve, but not mentioned the treatment history.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial. the study focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Rationale: The paper does not mention that the patients from whom the HIV isolates were obtained were part of a clinical trial. the study focuses on the in vitro activity of dolutegravir and the resistance profiles of various HIV-1 and HIV-2 strains, but it does not provide details about clinical trials involving the patients.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Rationale: The paper is about in vitro activity of dolutegravir, although the paper mentioned sample from INSTI-naïve individuals, the treatment history is not reported.

Answer: Not reported
""""""",118
31988104,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, the treatment history is not reported.

Rationale: The paper does not explicitly mention that the sequences were obtained from patient samples, but it does mention the use of patient-derived HIV-1 isolates.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the study is about selection of in vitro resistance to both TAF and the parent compound, which means the samples were not from HIV infected individuals.

Rationale: The paper reports in vitro drug susceptibility data by evaluating the phenotypic susceptibility of patient-derived HIV-1 isolates to TAF and TDF.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Samples with TFV genotypic and phenotypic data from an internal clinical database were selected (n = 42) based on sample availability and the presence of full mutations at positions 65 and 184 (no viral mixtures present).

Rationale: The paper mentions that 42 samples with TFV genotypic and phenotypic data were selected for  the study.

Answer: 42
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: our analysis focused on the use of patient-derived viruses rather than two single site-directed mutants to study the effect of the mutations on TAF and TFV susceptibility in a variety of genetic contexts.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: A 1463 bp DNA fragment from the RT gene was amplified and cloned into the pXXLAI proviral DNA vector as described,16 with some modifications.

Rationale: The paper mentions that a 1463 bp DNA fragment from the RT gene was amplified and cloned into the pXXLAI proviral DNA vector.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: our analysis focused on the use of patient-derived viruses rather than two single site-directed mutants to study the effect of the mutations on TAF and TFV susceptibility in a variety of genetic contexts.

Rationale: The paper does not specify the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: our analysis focused on the use of patient-derived viruses rather than two single site-directed mutants to study the effect of the mutations on TAF and TFV susceptibility in a variety of genetic contexts.

Rationale: The paper does not specify the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: our analysis focused on the use of patient-derived viruses rather than two single site-directed mutants to study the effect of the mutations on TAF and TFV susceptibility in a variety of genetic contexts.

Rationale: The paper mentioned the sample were from patient but without reporting the patient treatment history.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Samples with TFV genotypic and phenotypic data from an internal clinical database were selected (n = 42) based on sample availability and the presence of full mutations at positions 65 and 184 (no viral mixtures present).

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 with Thymidine Analog-Associated Mutations and M184V

Rationale: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: All viruses were evaluated against TAF and TFV in addition to the 3 NRTIs ABC, FTC, 3TC, and the protease inhibitor (PI) DRV as internal control compounds to benchmark the strength of the infections (Table 1).

Rationale: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, the treatment history is not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: All viruses were evaluated against TAF and TFV in addition to the 3 NRTIs ABC, FTC, 3TC, and the protease inhibitor (PI) DRV as internal control compounds to benchmark the strength of the infections (Table 1).

Rationale: The paper focuses on antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates, the treatment history is not reported.

Answer: Not reported
""""""",93
32601157,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not report on sequencing data from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper provides extensive data on the in vitro antiviral activities of CAB and BIC against various INSTI-resistant mutants, including EC ~50~ values, which are indicative of drug susceptibility.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on laboratory studies rather than field data and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on laboratory studies rather than field data and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the number of individuals from whom samples were obtained for sequencing, as it does not report on any patient data.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the countries from which sequenced samples were obtained, as it does not report on any patient data.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the years from which sequenced samples were obtained, as it does not report on any patient data.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing, as it does not provide any details on sequencing processes.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing the entire RT portion of the pol gene, spanning nucleotide 200 of protease to nucleotide 105 of integrase.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify any sequencing methods used, as it does not report on sequencing data or methodologies.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify any clinical specimens that were sequenced. It focuses on the antiviral efficacy of the drugs rather than on clinical sample data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any sequences obtained from individuals with virological failure. It primarily discusses the efficacy of the drugs against resistant mutants.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention any clinical trials involving patients. It discusses laboratory studies on drug efficacy without reference to clinical trial data.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had previously received ARV drugs. It focuses on the efficacy of the drugs against resistant mutants.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on drug classes received by individuals prior to sample sequencing, as it does not report on any patient data.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals prior to sample sequencing. It focuses on the efficacy of the drugs in vitro rather than on patient treatment history.

Answer: Not reported
""""""",77
33855437,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).""

Rationale: The paper mentions that clinical samples were obtained from patient samples, and viruses were amplified from treatment-naive persons.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""A cell-based in vitro phenotypic assay monitored the impact of the progressive accumulation of select mutations on drug susceptibility to doravirine, rilpivirine, etravirine and efavirenz.""

Rationale: The paper mentions that a cell-based in vitro phenotypic assay was used to monitor the impact of mutations on drug susceptibility.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).""

Rationale: The paper lists several GenBank accession numbers for the sequenced HIV isolates.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).""

Rationale: The paper lists several GenBank accession numbers for the sequenced HIV isolates.

Answer: MW484893, MW484894, MW484895, DQ380549, AF492618
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively). Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper lists 5 clinical samples from treatment-naïve persons and 5 clinical samples from patients bearing NRTI and NNRTI RAMS.

Answer: 10
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic analysis of all clinical isolates was performed at weeks 8 and 24 of selective drug pressure to evaluate the monitor the acquisition and accumulation of amino acid substitutions (i.e. drug resistance mutations).""

Rationale: The paper focuses on the sequencing of the reverse transcriptase (RT) gene, as it discusses mutations and resistance associated with NNRTIs and NRTIs, which target the RT gene.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Genotypic analysis of all clinical isolates was performed at weeks 8 and 24 of selective drug pressure to evaluate the monitor the acquisition and accumulation of amino acid substitutions (i.e. drug resistance mutations).""

Rationale: The paper mentions that genotypic analysis was performed, but it does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the exact type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from patients bearing common NRTI and NNRTI RAMs, which suggests that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Clinical samples were obtained through the Fonds de Recherche du Québec Santé-Réseau SIDA, obtained with ethics approval (Veritas) and informed consent. Viruses were amplified from treatment-naive persons harbouring WT variants, including 5326, 14637, 14969, 6343 and 4742 (GenBank accession numbers MW484893, MW484894, MW484895, DQ380549 and AF492618, respectively).30 Viruses were also amplified from patients bearing common NRTI and NNRTI RAMs, including 4242, 5555, 5652, 5686 and 5697 (GenBank Accession numbers OQ336290–4).""

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper mentions that viruses were amplified from treatment-naïve patients, drug-treated persons, and lab isolates, which means some sequences were from individuals who had previously received ARV drugs, the received drugs were not reported.

Answer: Not reported
""""""",113
34516245,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. It focuses on in vitro studies and does not mention depositing sequences in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide any information on the virological outcomes of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide any information on the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",61
35730213,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries where the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",55
35913500,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of genotypic drug resistance testing by Sanger sequencing and ultra-deep sequencing by Illumina MiSeq on plasma viral load specimens collected from patients.

Rationale: The paper describes the use of genotypic drug resistance testing by Sanger sequencing and ultra-deep sequencing by Illumina MiSeq on plasma viral load specimens collected from patients. This indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Between June 2021 and April 2022, 51 patients initiated LAI-ART, with 39 receiving at least 2 follow-up injections by database closure.

Rationale: The paper states that 51 patients initiated LAI-ART, and 39 received at least 2 follow-up injections.

Answer: 39
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Between June 2021 and April 2022.

Rationale: The paper mentions that patients initiated LAI-ART between June 2021 and April 2022.

Answer: 2021-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Of 15 patients who started with detectable viremia, 12 (80%; 95% CI, 55%–93%) had achieved and maintained viral suppression, including the patient with the baseline N155H mutation.

Rationale: The paper discusses patients who started with detectable viremia and achieved viral suppression, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses patients who started with detectable viremia and achieved viral suppression, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper discusses patients who started with detectable viremia and achieved viral suppression, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",70
35945163,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy""

Rationale: The paper discusses the use of long-acting cabotegravir and rilpivirine for people living with HIV-1, which implies that HIV sequences from patient samples were analyzed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper mentions that 35 people living with HIV-1 had samples obtained for HIV sequencing.

Answer: 35
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Included individuals were from ten countries, including 12 from the UK; 11 from the USA; two each from Belgium, Canada, Netherlands, and Switzerland; and one each from Portugal, Italy, South Korea, and Spain.""

Rationale: The paper lists the countries where the study was conducted, which implies that the sequenced samples were obtained from these locations.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Efficacy and safety data were available for 35 people living with HIV-1 who received cabotegravir LA + rilpivirine LA through the compassionate use programme from February 2016 through July 2020.""

Rationale: The paper provides the timeline for the enrollment of participants, which indicates the period during which the samples were obtained.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response""

Rationale: The paper mentions that sequences were obtained from individuals who experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""Compassionate use programmes facilitate early access to drugs in late-stage clinical development for patients who do not qualify for ongoing registrational studies and have serious or life-threatening conditions with prohibited or limited treatment options""

Rationale: The paper describes a compassionate use program, which is not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Most (63%) achieved or maintained virological suppression with intramuscular cabotegravir LA + rilpivirine LA Q4W.""

Rationale: The paper mentions that individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Cabotegravir LA + rilpivirine LA""

Rationale: The paper mentions that individuals received cabotegravir LA and rilpivirine LA, which are INSTI and NNRTI, respectively.

Answer: INSTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Cabotegravir LA + rilpivirine LA""

Rationale: The paper mentions that individuals received cabotegravir LA and rilpivirine LA.

Answer: Cabotegravir, Rilpivirine
""""""",82
36415058,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information about which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information about previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",52
36454248,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper explicitly states that HIV-1 *pol* sequences were recovered from patient samples, indicating that sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.

Rationale: The paper states that the sequences were deposited in GenBank, indicating that they were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: OM201778 -- OM201846

Rationale: The paper provides specific accession numbers for the sequenced HIV isolates, indicating where they can be found in the GenBank database.

Answer: OM201778 -- OM201846
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper states that plasma samples were collected from 76 HIV-infected children/adolescents, indicating the number of individuals from whom samples were obtained.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Panama.

Rationale: The paper mentions that the study was conducted in Panama, indicating the country of origin for the sequenced samples.

Answer: Panama
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper specifies the years during which the samples were collected, providing a specific range of years.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing, indicating that this process was not performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: HIV-1 *pol* sequences were recovered from 67 (88.2%) of 76 children/adolescents (median age 12 years), carrying 65 subtype B, 1 subtype G and 1 unique recombinant URF_A1B.

Rationale: The paper mentions that the *pol* gene was sequenced, which includes the protease (PR), reverse transcriptase (RT), and integrase (IN) genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux). The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region.

Rationale: The paper mentions the use of RT-PCR and nested PCR for amplification, but does not explicitly state the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples from 76 HIV-infected children/adolescents were collected during 2018--19.

Rationale: The paper specifies that plasma samples were used for sequencing, indicating the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper mentions that all treated children/adolescents had received NRTIs and were under virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper mentions that all treated children/adolescents had received ARV drugs, confirming that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper mentions that the individuals had received NRTIs, NNRTIs, PIs, and INSTIs, indicating the drug classes involved.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced.

Rationale: The paper mentions that the individuals had received NRTIs, NNRTIs, PIs, and INSTIs, but does not provide specific drug names.

Answer: Not reported
""""""",97
36519389,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data. It discusses the effects of switching from one antiretroviral therapy regimen to another, but it does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention making sequences publicly available. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which the sequenced samples were obtained. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning samples prior to sequencing. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were reported to have been sequenced. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the method used for sequencing. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The trial was approved by the University of the Witwatersrand's Human Research Ethics Committee (2204410) grant number: 2016-07-Wits RHI.

Rationale: The paper mentions that the trial was approved by the University of the Witwatersrand's Human Research Ethics Committee, indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drugs received by individuals in the study before sample sequencing. It discusses the results of a study on the effects of switching from one antiretroviral therapy regimen to another, but it does not mention HIV sequencing.

Answer: Not reported
""""""",90
36571282,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""For this study, we used the RT FASTA viral sequence from 50 naive patients diagnosed during the study period, with a broad representation of HIV subtypes in the cohort harboring V106I and no other NNRTI RAMs.""

Rationale: The paper explicitly states that RT FASTA viral sequences were used from 50 naive patients from cohort harboring V106I, which indicates that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on clinical outcomes, resistance testing, and patient data but does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""For this study, we used the RT FASTA viral sequence from 50 naive patients diagnosed during the study period, with a broad representation of HIV subtypes in the cohort harboring V106I and no other NNRTI RAMs.""

Rationale: The paper states that RT FASTA viral sequences were used from 50 naive patients from cohort harboring V106I.

Answer: 50
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""MeditRes HIV is a consortium that includes ART-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018--2021.""

Rationale: The paper mentions that the MediRes HIV consortium includes antiretroviral-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during the years 2018-2021.

Answer: France, Greece, Italy, Portugal, Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""MeditRes HIV is a consortium that includes ART-naive PWH newly diagnosed in France, Greece, Italy, Portugal, and Spain during 2018--2021.""

Rationale: The paper specifies that the samples were obtained from antiretroviral-naive PWH newly diagnosed during the years 2018-2021.

Answer: 2018-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""For this study, we used the RT FASTA viral sequence from 50 naive patients diagnosed during the study period, with a broad representation of HIV subtypes in the cohort harboring V106I and no other NNRTI RAMs.""

Rationale: The paper focuses on the reverse transcriptase (RT) gene, specifically discussing mutations in the RT gene.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.""

Rationale: The paper specifies that population sequencing was performed using the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not specify the exact type of clinical specimens sequenced, it mentions samples were from naïve patients, which means the samples were collected from plasma.

Rationale: The paper does not specify the exact type of clinical specimens sequenced, but it can be inferred that the samples were collected from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial. It describes the study as part of a larger effort to analyze HIV-1 genetic diversity in Mediterranean Europe.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Rationale: The paper specifies that the study included antiretroviral-naive PWH, indicating that the sequences were not from individuals who had previously received ARV drugs.

Answer: nan
""""""",102
36597160,"Here are the answers to the questions in the required format:

### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""We conducted a retrospective multicenter observational cohort study including adult patients with controlled HIV-1 infection on any stable ART regimen, who switched to E/C/F/TDF.""

Rationale: The paper does not explicitly mention HIV sequences from patient samples, but it does mention a retrospective multicenter observational cohort study including adult patients with controlled HIV-1 infection.

Answer: No

### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""382 patients with HIV RNA \< 50 copies/mL who switched to E/C/F/TDF were included in the study.""

Rationale: The paper mentions that 382 patients were included in the study.

Answer: 382

### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Evidence: ""We conducted a retrospective multicenter observational cohort study including adult patients with controlled HIV-1 infection on any stable ART regimen, who switched to E/C/F/TDF between February 2014 (date of approval of E/C/F/TDF in France) and August 2015.""

Rationale: The paper mentions that the study was conducted between February 2014 and August 2015.

Answer: 2014-2015

### Question 8: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported

### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypes were performed using Sanger sequencing.""

Rationale: The paper mentions that genotypes were performed using Sanger sequencing, but it does not specify which HIV genes were sequenced.

Answer: Not reported

### Question 10: What method was used for sequencing?

Evidence: ""Genotypes were performed using Sanger sequencing.""

Rationale: The paper mentions that Sanger sequencing was used for genotyping.

Answer: Sanger sequencing

### Question 11: What type of samples were sequenced?

Evidence: ""No evidence""

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Thirteen (3.5%) patients experienced virologic failure: eight had an HIV RNA ≥ 50 copies before W48 and five at week 48.""

Rationale: The paper mentions that 13 patients experienced virological failure.

Answer: Yes

### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""We conducted a retrospective multicenter observational cohort study including adult patients with controlled HIV-1 infection on any stable ART regimen, who switched to E/C/F/TDF.""

Rationale: The paper does not mention a clinical trial.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""382 patients with HIV RNA \< 50 copies/mL who switched to E/C/F/TDF were included in the study.""

Rationale: The paper mentions that patients had previously received ARV drugs.

Answer: Yes

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Before switching to E/C/F/TDF, a majority of patients received a combination of two NRTI and a third agent: ritonavir-boosted PI (PI/r) in 195/382 (51.0%), NNRTI in 84/382 (22.0%) and INSTI in 67/382 (17.5%) patients.""

Rationale: The paper mentions that patients received NRTI, PI, NNRTI, and INSTI before switching to E/C/F/TDF.

Answer: NRTI, PI, NNRTI, INSTI

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Before switching to E/C/F/TDF, a majority of patients received a combination of two NRTI and a third agent: ritonavir-boosted PI (PI/r) in 195/382 (51.0%), NNRTI in 84/382 (22.0%) and INSTI in 67/382 (17.5%) patients.""

Rationale: The paper mentions that patients received various drugs before switching to E/C/F/TDF, including ritonavir-boosted PI, NNRTI, and INSTI.

Answer: Ritonavir-boosted PI, NNRTI, INSTI",86
36645792,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does mention genotypic resistance testing and HIV-1 RNA measurements.

Rationale: The paper focuses on the clinical trial results of the TLD treatment in adults with HIV-1, but it does not explicitly mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on clinical outcomes such as efficacy, safety, and tolerability of the TLD treatment in adults with HIV-1, but does not include any in vitro drug susceptibility testing results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that participants had virologic failure on first-line TEE.

Rationale: The paper mentions that participants had virologic failure on first-line TEE, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study is a randomized, double-blind, placebo-controlled, phase 2 trial.

Rationale: The paper clearly states that the study is a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had previously received TEE.

Rationale: The paper mentions that participants had previously received TEE, which indicates that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received TEE.

Rationale: The paper mentions that participants had previously received TEE, which includes the drug classes NRTI (tenofovir and emtricitabine) and NNRTI (efavirenz).

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received TEE.

Rationale: The paper mentions that participants had previously received TEE, which includes the drugs tenofovir, emtricitabine, and efavirenz.

Answer: Tenofovir, Emtricitabine, Efavirenz",77
36659824,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence of HIV sequences from patient samples is reported in the paper.

Rationale: The paper does not mention any HIV sequences from patient samples, as it focuses on the efficacy, safety, and feasibility of using BIC/FTC/TAF as a first-line regimen in a same-day initiation strategy.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is reported in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing, as it focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is reported in the paper.

Rationale: The paper does not mention any publicly available sequences or provide accession numbers, indicating that no sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers for sequenced HIV isolates are reported in the paper.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence of HIV sequencing is reported in the paper.

Rationale: The paper does not report any HIV sequencing data, as it focuses on clinical outcomes and genotypic resistance testing rather than sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence of sequenced samples is reported in the paper.

Rationale: The paper does not mention any specific countries from which sequenced samples were obtained, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence of sequenced samples is reported in the paper.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning prior to sequencing is reported in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence of HIV gene sequencing is reported in the paper.

Rationale: The paper does not mention any specific HIV genes that were sequenced, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence of sequencing methods is reported in the paper.

Rationale: The paper does not mention any specific sequencing methods, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence of sample sequencing is reported in the paper.

Rationale: The paper does not specify which clinical specimens were sequenced, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of sequencing from individuals with virological failure is reported in the paper.

Rationale: The paper does not report any sequences obtained from individuals with virological failure, as it does not report any sequencing data.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The study was a national, prospective, single-arm study assessing the efficacy, safety and feasibility of BIC/FTC/TAF in a same-day initiation model.

Rationale: The paper describes a clinical trial study, indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence of HIV sequences from individuals who had previously received ARV drugs is reported in the paper.

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence of drug classes received by individuals before sample sequencing is reported in the paper.

Rationale: The paper does not mention any specific drug classes received by individuals before sample sequencing, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence of drugs received by individuals before sample sequencing is reported in the paper.

Rationale: The paper does not mention any specific drugs received by individuals before sample sequencing, as it does not report any sequencing data.

Answer: Not reported
""""""",81
36660819,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the reporting of HIV sequences from patient samples. However, it discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, which implies that HIV sequences may have been analyzed.

Rationale: The paper focuses on the clinical outcomes of the CAB+RPV LA treatment in adults with HIV-1, but does not explicitly mention the reporting of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not explicitly mention in vitro drug susceptibility data. However, it discusses the efficacy and safety of CAB+RPV LA in maintaining HIV-1 virologic suppression, which may imply some level of drug susceptibility testing.

Rationale: The paper focuses on the clinical outcomes of the CAB+RPV LA treatment in adults with HIV-1, but does not explicitly mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, but does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the specific years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide information on the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, but does not provide information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not explicitly mention the type of samples that were sequenced.

Rationale: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, but does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses virologic failure in the context of the CAB+RPV LA treatment, but does not explicitly mention the sequencing of individuals with virological failure.

Rationale: The paper focuses on the clinical outcomes of the CAB+RPV LA treatment in adults with HIV-1, but does not explicitly mention the sequencing of individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study is a phase 3b randomized, open-label, active-controlled, multicenter, parallel-group noninferiority study.

Rationale: The paper explicitly states that the study is a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, which implies that the individuals in the study had previously received ARV drugs.

Rationale: The paper focuses on the clinical outcomes of the CAB+RPV LA treatment in adults with HIV-1, which implies that the individuals in the study had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not explicitly mention the specific drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, but does not provide information on the specific drug classes that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not explicitly mention the specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper discusses the efficacy, safety, and tolerability of CAB+RPV LA in maintaining HIV-1 virologic suppression, but does not provide information on the specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",93
36694270,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples using a nested PCR method.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any information regarding the GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Overall, 62 HIV-1 patients with a median (IQR) age of 51 (38--64) years (51 ARV non- treated, including 49 naive; 11 ARV treated) were analysed""

Rationale: The paper explicitly states that 62 HIV-1 patients had samples obtained for HIV sequencing.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information regarding the country of origin for the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""We retrospectively collected matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022""

Rationale: The paper explicitly states that the samples were collected from June 2020 to June 2022.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide any information regarding whether samples were cloned prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper describes the use of a nested PCR method, but it does not explicitly state the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""RNA was extracted from 00 μL plasma and CFS.""

Rationale: The paper explicitly states that plasma and CSF samples were sequenced.

Answer: Plasma; CSF
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF""

Rationale: The paper suggests that some individuals had virological failure, but it does not explicitly state that sequences were obtained from these individuals.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF""

Rationale: The paper suggests that some individuals had previously received ARV drugs, but it does not explicitly state that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The NRTIs 3TC and TDF in multiple ARV treatment regimens are prone to cause 184 V/I and 65 R mutations; NNRTI EFV is prone to generate Y181C, G190A and K101E mutations; PI LPV/r appears to lead to M46I and V82A mutations""

Rationale: The paper mentions the use of NRTIs, NNRTIs, and PIs.

Answer: NRTI; NNRTI; PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The NRTIs 3TC and TDF in multiple ARV treatment regimens are prone to cause 184 V/I and 65 R mutations; NNRTI EFV is prone to generate Y181C, G190A and K101E mutations; PI LPV/r appears to lead to M46I and V82A mutations""

Rationale: The paper mentions the use of 3TC, TDF, EFV, and LPV/r.

Answer: Lamivudine (3TC), Tenofovir (TDF), Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r)
""""""",94
36706364,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""We conducted a single arm, prospective, interventional study in two primary care clinics in Khayelitsha, South Africa.""

Rationale: The paper mentions that the study was a single arm, prospective, interventional study, indicating that it was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",56
36738248,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the sequencing of HIV from patient samples, specifically mentioning the detection of mutations in the reverse transcriptase and integrase genes through Sanger and deep sequencing methods.

Rationale: The paper focuses on the sequencing of HIV from patient samples, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper does not report in vitro drug susceptibility data, focusing instead on clinical cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in HIV patients treated with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC).

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that this information was not provided.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 594 sample pairs from 527 PLHIV were included in the study.

Rationale: The paper mentions that 594 sample pairs from 527 PLHIV were included in the study, indicating that 527 individuals had samples obtained for HIV sequencing.

Answer: 527
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify any countries from which the sequenced samples were obtained.

Rationale: The paper does not specify any countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not provide any information regarding the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that samples were not cloned before sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of the protease (PR), reverse transcriptase (RT) and integrase (IN) regions of the HIV genome.

Rationale: The paper discusses the sequencing of the PR, RT, and IN regions of the HIV genome.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger sequencing and next-generation sequencing (NGS) for sequencing.

Rationale: The paper discusses the use of Sanger sequencing and NGS for sequencing.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples from PLHIV were used for sequencing.

Rationale: The paper mentions that plasma samples from PLHIV were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some individuals experienced virological failure (VF) and discusses the presence of low-frequency drug resistance mutations in these individuals.

Rationale: The paper mentions that some individuals experienced virological failure (VF) and discusses the presence of low-frequency drug resistance mutations in these individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals had previously received ARV therapy.

Rationale: The paper mentions that some individuals had previously received ARV therapy.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.
""""""",85
36751650,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study. Pol sequences were sequenced to analyze PDR and construct a genetic network.""

Rationale: The paper mentions that pol sequences were sequenced from individuals newly diagnosed with HIV in Guangxi, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not mention whether the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.""

Rationale: The paper states that a total of 1653 samples were successfully sequenced.

Answer: 1653
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study.""

Rationale: The paper mentions that the samples were obtained from individuals in Guangxi, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study.""

Rationale: The paper mentions that the samples were obtained from individuals in Guangxi from 2016 to 2020.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Pol sequences were sequenced to analyze PDR and construct a genetic network.""

Rationale: The paper mentions that pol sequences were sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""The PCR products were sent to the company for Sanger sequencing.""

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Plasma was separated within 12 hours of blood collection and stored at −80°C until further use.""

Rationale: The paper mentions that plasma was separated from blood samples and used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""No evidence""

Rationale: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",69
36779485,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention that sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",52
36795586,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence of HIV sequences from patient samples is reported in the paper.

Rationale: The paper does not mention any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is reported in the paper.

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is reported in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are reported in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not report the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not report the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning prior to sequencing is reported in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No HIV genes are reported to have been sequenced in the paper.

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No sequencing method is reported in the paper.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No sample type is reported in the paper.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of sequences from individuals with virological failure is reported in the paper.

Rationale: The paper does not mention any sequences from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is reported in the paper.

Rationale: The paper does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence of HIV sequences from individuals who had previously received ARV drugs is reported in the paper.

Rationale: The paper does not provide information on HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No drug classes are reported in the paper.

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No drugs are reported in the paper.

Rationale: The paper does not provide information on the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",66
36851704,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""HIV RNA was extracted from 1 mL of plasma (QIAamp Viral RNA Kit; QIAGEN, Valencia, CA, USA). *Protease* (HXB2 positions 6--99), *reverse transcriptase* (HXB2 positions 1--251), and *integrase* (HXB2 positions 1--288) HIV genes were amplified and sequenced using in-house-validated protocols [9, 10, 11].""

Rationale: The paper mentions that HIV RNA was extracted from patient plasma samples and that the protease, reverse transcriptase, and integrase HIV genes were amplified and sequenced.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 206 participants were enrolled in the survey;""

Rationale: The paper mentions that 206 participants were enrolled in the survey and had samples obtained for HIV sequencing.

Answer: 206
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018--2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART).""

Rationale: The paper mentions that the survey was conducted in Uruguay.

Answer: Uruguay
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018--2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART).""

Rationale: The paper mentions that the survey was conducted in 2018-2019.

Answer: 2018-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""*Protease* (HXB2 positions 6--99), *reverse transcriptase* (HXB2 positions 1--251), and *integrase* (HXB2 positions 1--288) HIV genes were amplified and sequenced using in-house-validated protocols [9, 10, 11].""

Rationale: The paper mentions that the protease, reverse transcriptase, and integrase HIV genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sanger sequencing was performed on a 3730xl Genetic Analyser (ThermoFisher, Waltham, MA, USA).""

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART. Plasma was separated within 12 h of collection;""

Rationale: The paper mentions that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""No evidence""

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The Ministry of Health of Uruguay implemented a cross-sectional nationally representative survey following the WHO-recommended methods [3].""

Rationale: The paper describes a cross-sectional survey and not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The proportion of individuals who reported previous exposure to ARV drugs was 35.6% (95% CI: 34.2--37.0%).""

Rationale: The paper mentions that some participants had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""NNRTI-based ART regimens were the most frequently prescribed (55.1%, 95% CI: 54--56.1%), followed by dolutegravir (DTG)-based regimens (29.4%, 95% CI: 28.4--30.4%), and PI/r-based regimens (11.7%, 95% CI: 11.0--12.6%)""

Rationale: The paper mentions that participants received NNRTI, INSTI, and PI/r-based regimens.

Answer: NNRTI, INSTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Among 231 eligible subjects, 105 patients were diagnosed with HIV infection prior to entering prenatal care at HFSE, and of these, 56 had previous exposure to cART.  The majority of women initiated cART during the second trimester of pregnancy, the most common first line regimen being zidovudine (ZDV) + lamivudine (3TC) + lopinavir/ritonavir (LPV/RTV) (n = 175). ""

Rationale: The paper mentions that participants received ZDV, 3TC, LPV, and RTV.

Answer: Zidovudine (ZDV), Lamivudine (3TC), Lopinavir/ritonavir (LPV/RTV)
""""""",97
36851760,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that dried blood spots (DBSs) were obtained from 107 HIV-1-infected children aged less than 15 years old living in two West African countries, Mali and Benin.

Rationale: The paper explicitly states that DBSs were obtained from HIV-1-infected children, indicating that the study involved HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: OQ435656-OQ435729

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: 107 HIV-1-infected children aged less than 15 years old living in two West African countries, Mali and Benin.

Rationale: The paper mentions that DBSs were obtained from 107 HIV-1-infected children.

Answer: 107
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Mali and Benin

Rationale: The paper mentions that the DBSs were obtained from HIV-1-infected children living in two West African countries, Mali and Benin.

Answer: Mali, Benin
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The DBSs were collected from 51 ART-treated children with virological failure between 2015 and 2016, and from 56 ART-naïve children between 2018 and 2020.

Rationale: The paper mentions the years during which the DBSs were collected.

Answer: 2015-2016, 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genetic sequencing of HIV integrase was successful in 75 samples.

Rationale: The paper explicitly states that the integrase gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the Sanger method was used for sequencing.

Rationale: The paper explicitly states that the Sanger method was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spots (DBSs) were obtained from HIV-1-infected children.

Rationale: The paper explicitly states that DBSs were used for sequencing.

Answer: Dried blood spots (DBSs)
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 51 ART-treated children with virological failure were included in the study.

Rationale: The paper explicitly states that the study included children with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 51 ART-treated children with virological failure were included in the study.

Rationale: The paper explicitly states that the study included children who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the children were receiving non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimens, and some were receiving both nucleoside-reverse-transcriptase inhibitor (NRTI)- and PI-based regimens.

Rationale: The paper explicitly states that the children were receiving NNRTI-based regimens, and some were receiving NRTI- and PI-based regimens.

Answer: NNRTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No specific drugs are mentioned in the paper.

Rationale: The paper does not provide specific information about the drugs received by the individuals in the study.

Answer: Not reported
""""""",75
36920025,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: Yes, the paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions the use of next-generation sequencing techniques and the analysis of proviral sequences, but it does not include specific accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates. It mentions the use of next-generation sequencing techniques and the analysis of proviral sequences, but it does not include specific accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, discussing various polymorphisms and resistance-associated mutations within this gene.

Rationale: The paper focuses on the integrase (IN) gene of HIV-1, discussing various polymorphisms and resistance-associated mutations within this gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on the previous treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",71
36931676,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples. Specifically, it mentions that HIV-DNA sequences were obtained from the peripheral blood of six participants over a period of 3 to ≥15 years of effective therapy.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, indicating that the study involved patient samples to obtain the HIV sequences.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on the persistence of HIV in memory CD4+ T-cells and the genetic analysis of HIV-DNA sequences. It does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs. It focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides the GenBank accession numbers for the datasets analyzed in the study in the Data Availability Statement section.

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Rationale: The paper provides specific GenBank accession numbers for the sequenced HIV isolates. It mentions that the generated HIV sequences were deposited in GenBank with accession numbers ranging from KR860607 to KR861345.

Answer: KR860607 to KR861345
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Rationale: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Rationale: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Answer: United States, Australia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the samples were obtained. It only mentions the duration of therapy and the time points of sample collection relative to the initiation of ART.

Rationale: The paper does not provide specific years for when the samples were obtained. It only mentions the duration of therapy and the time points of sample collection relative to the initiation of ART.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning the samples prior to sequencing. It describes single-proviral sequencing (SPS) which is a single genome sequencing method.

Rationale: The paper does not mention any cloning of samples prior to sequencing, focusing instead on the direct analysis of the plasma RNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of the HIV genome, specifically the p6-RT region.

Rationale: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of the HIV genome, specifically the p6-RT region.

Answer: Gag, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper describes the use of single-proviral sequencing (SPS) to obtain individual intracellular HIV-DNA sequences from the extracted DNA, but doesn't mention the sequencing method.

Rationale: The paper describes the use of single-proviral sequencing (SPS) to obtain individual intracellular HIV-DNA sequences from the extracted DNA, but doesn't mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Rationale: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Answer: Not reported
""""""",106
36961945,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We investigated whether deep sequencing of archived HIV DNA of antiretroviral-naïve persons with acute/early HIV infection could identify transmitted drug resistance mutations (DRM), per the IAS drug resistance algorithm, that are not detected by routine bulk (consensus) sequencing.""

Rationale: The paper discusses the sequencing of HIV DNA from patient samples to identify transmitted drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Of the 190 participants, EDI classifications were 37.9% acute (n=72/190), 10.5% very early (n=20/190), and 51.6% recent (n=98/190).""

Rationale: The paper mentions that 190 participants had samples obtained for HIV sequencing.

Answer: 190
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific information on the countries where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Samples were collected from January 2005 to February 2020 (Table S2).""

Rationale: The paper mentions that the samples were collected from January 2005 to February 2020.

Answer: 2005-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay (SeqIT GmbH & Co. KG, Kaiserlautern, Germany).""

Rationale: The paper mentions that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""NGS of HIV partial pol was performed to identify DRMs present in archived proviral DNA (peripheral blood mononuclear cells (PBMC)).""

Rationale: The paper mentions that next-generation sequencing (NGS) was used for sequencing.

Answer: Next-generation sequencing (NGS)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Genomic DNA was isolated from patient PBMCs (10^6 cells) using QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol.""

Rationale: The paper mentions that PBMC samples were sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Despite identifying both high frequency and low frequency DRMs in either archived proviral DNA or blood plasma, there was no evidence of viral rebound from any participants during the entire follow-up period, including the individuals identified with M184V/I and associated 3TC/FTC treatments.""

Rationale: The paper mentions that there was no evidence of virological failure in the participants.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""No evidence""

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Among 120 subjects, 81% were on antiretroviral therapy and had been treated for a median time of 7 years.""

Rationale: The paper mentions that some participants had previously received antiretroviral therapy.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Cumulative ART history included exposure to TDF (85%), AZT and/or d4T (57%) and 57% and 66% had received an NNRTI- or PI- based regimen respectively.""

Rationale: The paper mentions that the cumulative ART history included exposure to NRTIs, NNRTIs, and PIs.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Cumulative ART history included exposure to TDF (85%), AZT and/or d4T (57%) and 57% and 66% had received an NNRTI- or PI- based regimen respectively.""

Rationale: The paper specifies that the cumulative ART history included exposure to TDF (Tenofovir), AZT, d4T, NNRTIs, and PIs.

Answer: Tenofovir (TFV), Zidovudine (AZT), Stavudine (D4T)
""""""",86
36967989,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the collection or analysis of HIV sequences from patient samples. It focuses on the development of a machine learning model to predict HIV-1 protease resistance using genotypic, phenotypic, and molecular information.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We analyzed in vitro susceptibility test results on 2,725 HIV-1 protease isolates.""

Rationale: The paper mentions the analysis of in vitro susceptibility test results on HIV-1 protease isolates, indicating that it reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any information on the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide any information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide any information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide any information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",61
36982978,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that sequences were collected from patients of the French ANRS CO5 HIV-2 cohort, and from public databases.

Rationale: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions the study is about selection of in vitro resistance to both TAF and the parent compound, which means the samples were not from HIV infected individuals.

Rationale: The paper does not mention any in vitro drug susceptibility data for HIV-2 isolates from patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that all French HIV-2 sequences used in this study have been deposited on GenBank.

Rationale: The paper provides specific GenBank accession numbers for the sequences used in the study.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequences used in the study.

Rationale: The paper provides specific GenBank accession numbers for the sequences used in the study.

Answer: KP226396-KP226481, MW697236-MW697343, MW697344-MW697444, KP226314-KP226501, MW714050-MW714124
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 444 partial *pol* sequences were collected from 291 patients.

Rationale: The paper mentions that 444 partial *pol* sequences were collected from 291 patients.

Answer: 291
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the sequenced samples were obtained primarily from patients within the French ANRS CO5 HIV-2 cohort.

Rationale: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Answer: France
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that sequences were generated for drug resistance monitoring or research purposes within the French ANRS CO5 HIV-2 cohort since 1994.

Rationale: The paper mentions that sequences were generated for drug resistance monitoring or research purposes within the French ANRS CO5 HIV-2 cohort since 1994.

Answer: 1994-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper mentions that all squence were from other data base: French ANRS CO5 HIV-2 cohort, GenBank, and, Los Alamos National Laboratory.

Rationale: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that sequences from the *pol* (which includes protease and reverse transcriptase), *env*, *vif*, and LTR regions were collected and analyzed.

Rationale: The paper mentions that sequences from the *pol* (which includes protease and reverse transcriptase), *env*, *vif*, and LTR regions were collected and analyzed.

Answer: PR, RT, Vif, Env, LTR
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that all squence were from other data base: French ANRS CO5 HIV-2 cohort, GenBank, and, Los Alamos National Laboratory.

Rationale: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the full pol gene from 53 samples was sequenced from frozen plasma collected between 1997 and 2008.

Rationale: The paper specifies that the full pol gene from 53 samples was sequenced from frozen plasma collected between 1997 and 2008.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from treatment-experienced patients, and these sequences contain common RT and PR drug resistance mutations.

Rationale: The paper mentions that sequences were obtained from treatment-experienced patients, and these sequences contain common RT and PR drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Rationale: The paper focuses on the collection and analysis of sequences from multiple patients and public databases.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that sequences were obtained from treatment-experienced patients, and these sequences contain common RT and PR drug resistance mutations.

Rationale: The paper mentions that sequences were obtained from treatment-experienced patients, and these sequences contain common RT and PR drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients had been exposed to 2-4 NRTIs and some were treated with 2-4 NRTIs + 1 or 2 PIs.

Rationale: The paper mentions that patients had been exposed to 2-4 NRTIs and some were treated with 2-4 NRTIs + 1 or 2 PIs.

Answer: NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the drugs used by individuals were not reported.

Rationale: The paper mentions that the drugs used by individuals were not reported.

Answer: Not reported
""""""",92
37017009,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Resistance genotyping was performed using next-generation sequencing technologies"" and that ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube"" for the purpose of HIV drug resistance testing.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples for the purpose of drug resistance testing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on genotyping and identifying drug resistance mutations from patient samples, but does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention depositing the sequences in a public database or making them available for download.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or providing accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""899 participants from 40 facilities from eight provinces"" were included in the study analysis.

Rationale: The paper explicitly states that 899 participants had samples obtained for HIV sequencing.

Answer: 899
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in South Africa.

Rationale: The paper explicitly states that the study was conducted in South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from March 2017 to March 2019.

Rationale: The paper explicitly states that the study was conducted from March 2017 to March 2019.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper mentions the use of next-generation sequencing technologies, but does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene"".

Rationale: The paper explicitly states that the protease gene and the first 250 amino acids of the reverse transcriptase gene were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Resistance genotyping was performed using next-generation sequencing technologies"".

Rationale: The paper explicitly states that next-generation sequencing technologies were used for sequencing.

Answer: Next-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube"" for the purpose of HIV drug resistance testing.

Rationale: The paper explicitly states that whole blood samples were used for sequencing.

Answer: Whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""Participants had to be aged ≤19 years, on ART for a minimum of 1 year (±3 months), and with suggestive evidence of VF performed within the previous 6 months"".

Rationale: The paper explicitly states that participants had to have virological failure on a treatment regimen to be included in the study.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a cross-sectional study design and does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Participants had to be aged ≤19 years, on ART for a minimum of 1 year (±3 months)"".

Rationale: The paper explicitly states that participants had to have been on ART for at least 1 year, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""Amongst participants receiving PI-based regimens, adjusted total HIVDR was detected in 80.6% (95% CI 73.1%--86.4%)"" and ""Amongst participants receiving NNRTI-based regimens, HIVDR was detected in 94.9% (95% CI 90.0%--97.4%)"".

Rationale: The paper explicitly states that participants received PI-based and NNRTI-based regimens before sample sequencing.

Answer: PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The majority were receiving ritonavir-boosted lopinavir-based regimens (97.1%), whilst 2.9% were receiving ritonavir-boosted atazanavir"" and ""The majority were receiving efavirenz-based regimens (98.7%); seven participants were receiving nevirapine"".

Rationale: The paper explicitly states that participants received ritonavir-boosted lopinavir, ritonavir-boosted atazanavir, efavirenz, and nevirapine before sample sequencing.

Answer: Ritonavir-boosted lopinavir, Ritonavir-boosted atazanavir, Efavirenz, Nevirapine
""""""",93
37029656,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the analysis of HIV sequences from patient samples.

Rationale: The paper focuses on the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of HIV sequence analysis from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance and the prevalence of resistance mutations, but it does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making sequences publicly available.

Rationale: There is no mention of GenBank accession numbers or any other form of public sequence deposition in the provided content.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: There is no mention of GenBank accession numbers in the provided content.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the countries from which the sequenced samples were obtained.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted over the period 2009-2019.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, and it provides the time frame during which the study was conducted.

Answer: 2009-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance and the prevalence of resistance mutations, but it does not report any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not explicitly mention which HIV genes were sequenced.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance and the prevalence of resistance mutations, but it does not provide direct evidence of the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance and the prevalence of resistance mutations, and it mentions the use of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not explicitly mention the type of samples that were sequenced.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not explicitly mention the analysis of sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of the analysis of sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the patients were part of a clinical trial.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, but it does not provide direct evidence of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not explicitly mention the analysis of HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, indicating that the individuals had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not explicitly mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, indicating that the individuals had not previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not explicitly mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper discusses the evaluation of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV, indicating that the individuals had not previously received ARV drugs.

Answer: Not reported
""""""",91
37039023,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study"" and that ""All samples were successfully sequenced.""

Rationale: The paper clearly states that HIV sequences were obtained from patient samples, as it describes the sequencing process and the number of patients included in the study.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that ""The raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The paper explicitly states that the sequencing reads were made publicly available through the Sequence Read Archive.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study.""

Rationale: The paper clearly states that a total of 86 patients had samples obtained for HIV sequencing.

Answer: 86
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients in Rio de Janeiro (RJ) and Rio Grande do Sul (RS), both located in Brazil.

Rationale: The paper clearly states that the samples were collected from patients in Brazil.

Answer: Brazil
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""All samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017.""

Rationale: The paper clearly states that the samples were collected between 2016 and 2018.

Answer: 2016-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""Protease, reverse transcriptase, integrase and envelope regions are known to harbour antiretroviral resistance mutations, and all 86 study samples had at least one of these regions analysed.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, integrase, and envelope regions were analyzed.

Answer: PR, RT, IN, Env
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Libraries were quantified in Qubit 3 (Life Technologies, Carlsbad, CA, USA) and sequenced using the Illumina MiSeq platform with a paired-end 2 × 251 protocol.""

Rationale: The paper explicitly states that the Illumina MiSeq platform was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Six millilitres of whole peripheral blood was collected from all patients who agreed to participate in the study and signed the informed consent.""

Rationale: The paper clearly states that whole peripheral blood samples were collected from patients.

Answer: Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""All patients were in therapeutic success at the time of their inclusion in our study.""

Rationale: The paper clearly states that all patients were in therapeutic success, indicating that no sequences were obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any clinical trial, and the focus is on the analysis of patient samples.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""Most patients (RJ, 76.1%; RS, 95.0%) reported being infected through sexual transmission"" and that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper mentions that the patients had previously received ARV drugs, as it describes the therapeutic regimens used by the patients.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper mentions that the patients received NRTIs (TDF, 3TC), NNRTIs (EFV), and possibly other drug classes.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper explicitly states that the patients received TDF, 3TC, and EFV.

Answer: Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)
""""""",102
37042390,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019. Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper mentions that genotypic resistance testing was performed on patient samples to identify drug resistance mutations in the integrase, reverse transcriptase, and protease genes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that 87 patients were started on third-line ART, and genotypic resistance testing was performed on these patients.

Answer: 87
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This single-centre observational study was done at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.""

Rationale: The paper mentions that the study was conducted in India.

Answer: India
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that the patients were started on third-line ART between July 2016 and December 2019.

Answer: 2016-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper mentions that the integrase, reverse transcriptase, and protease genes were sequenced.

Answer: IN, RT, PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""Sequencing was done by a third-party commercial organization (Medauxin) using an Applied Biosystem 3730xl DNA Analyzer.""

Rationale: The paper mentions that sequencing was done using an Applied Biosystem 3730xl DNA Analyzer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood was collected from patients into EDTA tubes and used for CD4 estimation; in parallel, plasma was separated following centrifugation at 2000 rpm at 4°C for 10 min and stored at −80°C until viral RNA isolation.""

Rationale: The paper mentions that whole blood and plasma samples were collected from patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Among the 13 patients who did not attain virological suppression at 12 months, genotyping could be done in only 12.""

Rationale: The paper mentions that genotyping was performed on patients who did not attain virological suppression at 12 months.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This single-centre observational study was done at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.""

Rationale: The paper describes the study as an observational study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper mentions that the patients were started on third-line ART, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper mentions that the patients received a regimen containing an integrase inhibitor (raltegravir), a protease inhibitor (darunavir), and a booster (ritonavir).

Answer: INSTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper mentions that the patients received raltegravir, darunavir, and ritonavir.

Answer: Raltegravir, Darunavir, Ritonavir
""""""",90
37052343,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on clinical outcomes and virological nonsuppression outcomes but does not mention in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making sequences publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or the number of individuals who had samples obtained.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or the countries from which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or the years from which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were reported to have been sequenced.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or the specific genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention any sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or previous drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper discusses virological outcomes and antiretroviral treatment but does not mention HIV sequencing or previous drug use.

Answer: Not reported
""""""",78
37071019,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the collection of samples from HIV-infected individuals.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""We performed resistance assays using TZM-bl cells and various concentrations of DTG or RAL (Fig. 4), which generated EC50s for each virus as well as fold change (FC) values (Table 2). Although the primary H51Y substitution did not confer resistance against DTG or RAL (FC values of 1.25 and 0.98, respectively), consistent with previous results (11), the addition of R262K did result in low-level but significant biochemical resistance to DTG but not to RAL (FC values of 1.9 and 0.92, respectively).""

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to dolutegravir (DTG) and raltegravir (RAL) using short-term resistance assays with TZM-bl cells.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the collection of samples from HIV-infected individuals.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The characterization of HIV-1 reservoir from peripheral blood mononuclear cells was performed using next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq).""

Rationale: The paper mentions the use of full-length individual proviral sequencing (FLIP-Seq) to analyze the HIV-1 reservoir. This indicates that the full genome of the HIV-1 provirus was sequenced.

Answer: Full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the treatment history of the individuals.

Answer: Not reported
""""""",77
37085698,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, indicating that the study involved sequencing HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not mention conducting in vitro drug susceptibility tests, indicating that it does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that the sequences described in the article have been deposited in the GenBank, indicating that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.

Rationale: The paper explicitly states that the sequences described in the article have been deposited in the GenBank under the accession numbers MW560010 to MW560058.

Answer: MW560010 to MW560058
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper states that 49 study participants had samples obtained for HIV sequencing.

Answer: 49
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: This is a cross-sectional health facility-based study involving drug-naive HIV-1 infected study participants from voluntary VCT centers in Addis Ababa.

Rationale: The paper specifies that the samples were collected from HIV-1-infected patients in Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Accordingly, forty-nine volunteered adult (≥ 18 years old) study participants from voluntary VCT centers in Addis Ababa were consecutively enrolled in this study from June to December 2018.

Rationale: The paper mentions that the samples were collected from June to December 2018.

Answer: 2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.

Rationale: The paper mentions that the IN region of the HIV-1 gene was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: Purified amplicons were then sequenced with Sanger DNA sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), and run on the ABI PRISM® 3500 xL automated Genetic Analyzer.

Rationale: The paper describes the use of Sanger DNA sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma was then separated by centrifugation for 10 min at 3000 rpm and stored in deep freeze (− 80 °C) till required for laboratory investigation.

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that the patients were experiencing virological failure on a treatment regimen.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study participants were drug-naive HIV-1 infected individuals.

Rationale: The paper does not mention that the individuals had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper does not mention any drug classes being received by the individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper does not mention any drugs being received by the individuals before sample sequencing.

Answer: Not reported
""""""",81
37104815,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV total DNA, ultra-sensitive plasma viral load (USpVL) and semen VL were measured in the first 121 participants.

Rationale: The paper involves the analysis of HIV sequences from patient samples, including total DNA, USpVL, and semen VL.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the first 121 participants had their treatment switched to the intermittent strategy, and all participants were followed for an additional 48 weeks.

Rationale: The paper states that 121 participants were included in the study.

Answer: 121
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries where the samples were obtained.

Rationale: The paper does not provide information on the countries where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were screened from 7 September 2017 to 22 January 2018.

Rationale: The paper provides the timeline for the enrollment of participants, which indicates the period during which the samples were obtained.

Answer: 2017-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: There is no reference to cloning in the methods or results sections of the paper.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that Sanger and ultra-deep sequencing (UDS) were performed for the reverse transcriptase (RT), protease (PR) and integrase (INT) regions.

Rationale: The paper specifies that the genes sequenced included those related to reverse transcriptase, protease, and integrase.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger and ultra-deep sequencing (UDS) were performed using Illumina technology.

Rationale: The paper describes the use of Sanger sequencing and ultra-deep sequencing using Illumina technology.

Answer: Sanger sequencing, Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood plasma samples for ultra-sensitive plasma VL (USpVL) were collected at D0, W4, W12, W24, W36 and W48.

Rationale: The paper specifies that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that resistance was retrospectively evaluated for participants with VF (pVL >50 copies/mL, confirmed within 4 weeks).

Rationale: The paper describes the analysis of sequences from individuals who experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was registered in ClinicalTrials.gov (NCT03256422) and EudraCT (2017-000040-17).

Rationale: The paper describes a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had a long duration of suppressed HIV viraemia, with 88.2% of participants having experienced no prior VF.

Rationale: The paper implies that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the cART regimens were based on INSTIs for 47.1%, NNRTIs for 47.1% and PIs for 5.8% of participants.

Rationale: The paper lists the drug classes used in the study.

Answer: INSTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the baseline NRTI backbone consisted of tenofovir/emtricitabine or tenofovir alafenamide/emtricitabine for 76.0% of participants and abacavir/lamivudine for 24.0%.

Rationale: The paper lists the specific drugs used in the study.

Answer: Tenofovir, Emtricitabine, Tenofovir alafenamide, Abacavir, Lamivudine
""""""",86
37112971,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper explicitly states that HIV-1 pol-gene fragment sequences were analyzed from patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on the prevalence of HIV-1 drug resistance and the genetic analysis of HIV-1 sequences from patient samples. It does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.

Rationale: GenBank accession numbers listed in paper

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The HIV-1 sequences generated from this study are available in the NCBI database with the GenBank accession numbers MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.

Rationale: GenBank accession numbers listed in paper

Answer: MH062016- MH062024, MH062026- MH062029, MH062125- MH062138, MK931539- MK931547, MK931784, MK931789- MK931801, MK931912- MK931931, MK931933, MK931934, MK931937, MK931939, MK931940, MK931942, MK931943, MK931945, MK931947- MK931964, MK931996, MK931997, MK931999- MK932016, and MW483846- MW484805.
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper states that 1071 HIV-1 pol-gene fragment sequences were analyzed from patients.

Answer: 1071
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: The paper explicitly lists the countries from which the sequenced samples were obtained.

Answer: Armenia, Azerbaijan, Belarus, Russia, Tajikistan, Uzbekistan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: We analyzed 1071 HIV-1 pol-gene fragment sequences (2253–3369 bp) from patients who were initiating or reinitiating first-line ART in six EECA counties, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), between 2017 and 2019.

Rationale: Paper mentioned the patients are ""between 2017 and 2019""

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper does not mention sample cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: Paper mentioned ""pol-gene region encoding a protease and part of a reverse transcriptase""

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper mentions the use of an AmpliSens1 HIV-Resist-Seq kit for RNA extraction and sequencing, which does not fall under the common categories of Sanger or next-generation sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: An AmpliSens1 HIV-Resist-Seq kit (Central Research Institute of Epidemiology, Russia) was used for RNA extraction from blood plasma samples, and for amplification and sequencing of the HIV pol-gene region encoding a protease and part of a reverse transcriptase

Rationale: The paper mentions that RNA was extracted from blood plasma samples for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentions that  the study included patients who were initiating or reinitiating first-line ART, which doesn't mean that patients have experienced virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Enrollment took place at AIDS clinics in six countries, i.e., Armenia (n = 120), Azerbaijan (n = 96), Belarus (n = 158), Russia (n = 465), Tajikistan (n = 54), and Uzbekistan (n = 178), as part of the cross-sectional, retrospective, surveillance study REZEDA-1 in EECA between January 2017 and February 2019.

Rationale: The paper describes  the study as a cross-sectional, retrospective, surveillance study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentioned that patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.  The study didn't mention the specific drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentioned that patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.  The study didn't mention the specific drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: To be included, patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.

Rationale: The paper mentioned that patients had to be at least 18 years old, ART-naïve or have prior drug exposure for treating HIV infection (with interruption for less than three months) or for prophylaxis, and be initiating or reinitiating first-line ART.  The study didn't mention the drugs.

Answer: Not reported
""""""",160
37147875,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of blood samples from the patient to identify drug-resistant variants and mentions the use of genotypic resistance testing, indicating that HIV sequences were reported.

Rationale: The paper discusses the analysis of blood samples from the patient to identify drug-resistant variants and mentions the use of genotypic resistance testing, indicating that HIV sequences were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any specific in vitro drug susceptibility data. It focuses on the clinical case and the emergence of resistance mutations in the context of treatment.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single patient case throughout the study.

Rationale: The focus of the paper is on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which the sequenced samples were obtained.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing and finding of drug resistance mutations on protease, revserse transcriptase, and integrase genes.

Rationale: The paper mentions the sequencing and finding of drug resistance mutations on protease, revserse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Sanger technology for genotypic resistance testing, and NGS method.

Rationale: The paper mentions the use of Sanger technology for genotypic resistance testing, and NGS method, indicating that this was the method used for sequencing.

Answer: Sanger sequencing; NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were analyzed, indicating that this was the clinical specimen type used for sequencing.

Rationale: The paper specifies that plasma samples were analyzed, indicating that this was the clinical specimen type used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses a patient who experienced virological failure while on treatment, confirming that sequences were obtained from such individuals.

Rationale: The paper discusses a patient who experienced virological failure while on treatment, confirming that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper discusses a patient with a history of antiretroviral drug treatments.

Rationale: The paper discusses a patient with a history of antiretroviral drug treatments.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs that belong to NRTI, NNRTI, PI, INSTI.

Rationale: The paper lists various antiretroviral drugs that belong to NRTI, NNRTI, PI, INSTI.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that were part of the patient's treatment regimen.

Rationale: The paper lists specific antiretroviral drugs that were part of the patient's treatment regimen.

Answer: Dolutegravir (DTG), Emtricitabine (FTC), Tenofovir disoproxil fumarate (TDF), Doravirine, Lamivudine (3TC), Abacavir (ABC)
""""""",76
37272233,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV drug resistance mutations in people with HIV in Korea, and it mentions that resistance mutation sequencing by PCR was performed for each ARV class.

Rationale: The paper focuses on the analysis of HIV drug resistance mutations, which involves sequencing HIV samples from patients. Although it does not explicitly state that HIV sequences were obtained from patient samples, the context implies that sequencing was performed on patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of HIV drug resistance mutations and their trends over time, but it does not discuss any in vitro experiments or data related to drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention anything about making the sequences publicly available, and it does not provide any accession numbers or links to public databases.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers, and it does not provide any information about depositing the sequences in public databases.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper analyzed a total of 248 people with HIV (PWH) who were newly diagnosed with HIV infection between January 2010 and December 2020.

Rationale: The paper mentions that 248 PWH were analyzed, but it does not explicitly state that all of them had samples obtained for HIV sequencing. However, the context implies that sequencing was performed on all of them.

Answer: 248
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples, but it mentions that the study was conducted at a 750-bed municipal hospital in Korea.

Rationale: The paper does not explicitly state the country of origin for the sequenced samples, but it implies that the samples were obtained from Korea.

Answer: Korea
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study included adults who were newly diagnosed with HIV infection between January 2010 and December 2020.

Rationale: The paper explicitly states the time period during which the samples were obtained.

Answer: 2010-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning the samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that resistance mutation sequencing by PCR was performed for each ARV class (nucleoside reverse transcriptase inhibitor [NRTI], non-nucleoside reverse transcriptase inhibitor [NNRTI], protease inhibitor [PI], and integrase strand transfer inhibitor [INSTI]).

Rationale: The paper mentions that sequencing was performed for each ARV class, which implies that the corresponding HIV genes were sequenced.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that resistance mutation sequencing by PCR was performed for each ARV class.

Rationale: The paper explicitly states that PCR was used for sequencing.

Answer: PCR
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not explicitly state the type of samples that were sequenced, but it mentions that resistance mutation sequencing by PCR was performed for each ARV class.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that resistance to only one class of ARV was detected in 27 patients and resistance to two classes of ARVs were detected in three patients.

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it mentions that resistance was detected in some patients.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included adults who were newly diagnosed with HIV infection between January 2010 and December 2020, and it does not explicitly state that they had previously received ARV drugs.

Rationale: The paper does not provide any information about previous ARV treatment.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included adults who were newly diagnosed with HIV infection between January 2010 and December 2020, and it does not explicitly state which drug classes were received before sample sequencing.

Rationale: The paper does not provide any information about previous ARV treatment.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included adults who were newly diagnosed with HIV infection between January 2010 and December 2020, and it does not explicitly state which drugs were received before sample sequencing.

Rationale: The paper does not provide any information about previous ARV treatment.

Answer: Not reported
""""""",92
37279764,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 sequences were obtained from newly diagnosed patients enrolled at Shenzhen from January 2011 to December 2019.

Rationale: The paper specifically states that HIV-1 sequences were obtained from patient samples, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and molecular transmission networks, but does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the partial pol sequences were deposited in GenBank (GenBank accession no. MW947591–MW957968, OP058117–OP058658).

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, confirming their availability.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the partial pol sequences were deposited in GenBank (GenBank accession no. MW947591–MW957968, OP058117–OP058658).

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates, confirming their availability.

Answer: MW947591–MW957968, OP058117–OP058658
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 12,320 participants with demographic data and partial pol sequences were included in this study.

Rationale: The paper states that 12,320 participants had samples obtained for HIV sequencing.

Answer: 12,320
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Shenzhen, China.

Rationale: The paper specifies that the study was conducted in Shenzhen, China, and all the sequenced samples were obtained from this location.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from January 2011 to December 2019.

Rationale: The paper specifies that the study was conducted from January 2011 to December 2019.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial pol gene region (HXB2: 2252–3255) was sequenced.

Rationale: The paper specifically mentions that the partial pol gene region was sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously.

Rationale: The paper does not explicitly mention the sequencing method, but it mentions that sequencing was performed as described previously, which may imply Sanger sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood samples were collected from patients.

Rationale: The paper specifies that blood samples were collected from patients, indicating that plasma samples were likely used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included treatment-naive individuals, but it also mentions that some individuals were on antiretroviral therapy.

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it mentions that some individuals were on antiretroviral therapy, which may imply that some individuals experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial, suggesting that this information is not available.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals were on antiretroviral therapy.

Rationale: The paper mentions that some individuals were on antiretroviral therapy, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals were on antiretroviral therapy, but it does not specify the drug classes.

Rationale: The paper does not explicitly mention the drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals were on antiretroviral therapy, but it does not specify the drugs.

Rationale: The paper does not explicitly mention the drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",83
37327289,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma of 64 HIV-1 infected, drug-naïve subjects with CD4+ T-cell counts < 200/μl.

Rationale: The paper specifically mentions that the subjects were drug-naïve, meaning they had not received antiretroviral treatment before the samples were obtained, and that HIV-1 RNA was extracted from plasma of the subjects.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on sequencing and identifying drug resistance mutations in patient samples but does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the pol sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].

Rationale: The paper explicitly states that the sequences have been archived in the DDBJ Nucleotide Database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the pol sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].

Rationale: The paper explicitly states that the sequences have been archived in the DDBJ Nucleotide Database.

Answer: LC723952-LC724015
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 64 HIV-seropositive plasma samples were collected from FSWs between November 2020 and April 2021.

Rationale: The paper specifically mentions that 64 plasma samples were collected from FSWs.

Answer: 64
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, Kenya.

Rationale: The paper specifically mentions that the participants were recruited from Nairobi County, Kenya.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the participants were recruited between November 2020 and April 2021.

Rationale: The paper specifically mentions the recruitment period.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the pol gene was amplified and genotyped using sanger sequencing.

Rationale: The paper specifically mentions that the pol gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used for the pol gene sequencing.

Rationale: The paper specifically mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma of 64 HIV-1 infected, drug-naïve subjects with CD4+ T-cell counts < 200/μl.

Rationale: The paper specifically mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on treatment-naïve individuals and does not mention virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a cross-sectional study design and does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifically mentions that the subjects were drug-naïve, meaning they had not received antiretroviral treatment before the samples were obtained.

Rationale: The paper focuses on treatment-naïve individuals.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper focuses on treatment-naïve individuals and does not mention previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper focuses on treatment-naïve individuals and does not mention previous ARV drug use.

Answer: Not reported
""""""",78
37340869,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.""

Rationale: The paper discusses the sequencing of HIV-1 from patient samples, specifically the integrase gene, to determine the subtype and presence of polymorphisms.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""Rilpivirine susceptibility was assessed in HIV-1 subtype B and A1 containing reverse transcriptase mutations observed in participants with CVF. HIV-1 subtype B L74I and L74I/G140R mutants and HIV-1 subtype A6 I74L and I74/G140R mutants remained susceptible to cabotegravir; L74I/Q148R double mutants exhibited reduced susceptibility in HIV-1 subtypes B and A6 (half maximal effective capacity fold change, 4.4 and 4.1, respectively).""

Rationale: The paper reports in vitro drug susceptibility data for rilpivirine and cabotegravir against various HIV-1 strains and mutations.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.""

Rationale: The paper specifies that three participants with confirmed virologic failure (CVF) had their HIV-1 sequences analyzed and reported mutations.

Answer: 3
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""All 3 participants with CVF were from Russia and had the integrase polymorphism L74I at baseline.""

Rationale: The paper specifies that all three participants with confirmed virologic failure (CVF) were from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""All 3 FLAIR study participants receiving LA therapy with CVF were initially reported as having HIV-1 subtype A1 based on a commercial genotyping algorithm that only used protease (PR) and reverse transcriptase (RT) sequences. Given that the FLAIR participants with CVF presented with integrase mutations and cabotegravir resistance, their HIV-1 subtype was further evaluated with integrase sequences using the LANL reference library that contained additional HIV-1 subtypes, including A3, A4, and A6.""

Rationale: The paper mentions the sequencing of protease (PR), reverse transcriptase (RT), and integrase (IN) genes in the context of HIV-1 subtype classification and drug susceptibility studies.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact sequencing method used for the sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Of 283 FLAIR study participants who received LA therapy, 3 participants (1%) had confirmed virologic failure (CVF), defined as 2 consecutive plasma HIV-1 RNA levels $200 copies/mL.""

Rationale: The paper mentions that confirmed virologic failure (CVF) was defined based on plasma HIV-1 RNA levels, indicating that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HIV-1 that was originally classified as subtype A1 and contained the baseline integrase polymorphism L74I; updated classification algorithms reclassified all 3 as HIV-1 subtype A6.""

Rationale: The paper discusses sequences obtained from individuals who experienced confirmed virologic failure (CVF) while on long-acting cabotegravir and rilpivirine therapy.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The phase III FLAIR study evaluated the efficacy of monthly cabotegravir LA 1 rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper mentions that the participants were part of the FLAIR study, which is a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir 1 rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper discusses participants who were on long-acting cabotegravir and rilpivirine therapy, indicating they had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir 1 rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper mentions the study is about   participants receive a regimen that included dolutegravir, abacavir, and lamivudine, comparing with receiving long-acting cabotegravir and rilpivirine.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir 1 rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression.""

Rationale: The paper mentions the study is about   participants receive a regimen that included dolutegravir, abacavir, and lamivudine, comparing with receiving long-acting cabotegravir and rilpivirine.

Answer: Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC), Cabotegravir (CAB), Rilpivirine (RPV)
""""""",116
37358226,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information about the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",53
37376649,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay, which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper explicitly states that HIV-1 proviral DNA genotyping was conducted, which implies that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the clinical outcomes and resistance mutations in patients but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 734 participants had retrospective proviral DNA testing performed on available baseline samples.

Rationale: The paper explicitly states that 734 participants had retrospective proviral DNA testing performed.

Answer: 734
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not specify the exact years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: There is no reference to cloning in the methods or results sections of the paper.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay, which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper explicitly states that the HIV-1 polymerase region was analyzed, which includes the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the GenoSure Archive assay uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Rationale: The paper explicitly states that NGS was used for sequencing.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay.

Rationale: The paper explicitly states that proviral DNA was used for genotyping.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results.

Rationale: The paper explicitly states that participants with virological failure were excluded.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was conducted in accordance with the Declaration of Helsinki and national and institutional standards.

Rationale: The paper explicitly states that the study was conducted in accordance with clinical trial standards.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results.

Rationale: The paper explicitly states that participants with prior ARV drug resistance were excluded.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",79
37381002,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection and analysis of HIV sequences from patient samples, specifically mentioning the amplification of the partial pol gene fragment of HIV-1 virus from plasma samples.

Rationale: The paper explicitly states that the study involved sequencing HIV sequences from patient samples, providing details on the methods used for RNA extraction, PCR amplification, and Sanger sequencing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility, and does not provide any information on in vitro testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information on the public availability of the sequences.

Rationale: The paper does not mention depositing the sequences in a public database or providing access to the sequence data.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or providing accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 398 viral pol gene sequences were successfully sequenced from 450 people living with HIV who had received antiviral therapy for more than 1 year.

Rationale: The paper explicitly states the number of individuals from whom samples were obtained for sequencing.

Answer: 398
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples, but it does mention that the study was conducted in Suzhou City, China.

Rationale: The paper does not provide explicit information on the country of origin, but it can be inferred that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from 2017 to 2020.

Rationale: The paper explicitly states the time frame during which the samples were collected.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper describes direct sequencing of the amplified PCR products, which suggests that cloning was not performed.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial pol gene fragment of HIV-1 virus was amplified and sequenced, including the full length of the protease (PR) gene and the first 300 amino acids of the reverse transcriptase (RT) gene.

Rationale: The paper explicitly states the specific genes that were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used to obtain the sequences of the pol gene fragments.

Rationale: The paper explicitly states the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for RNA extraction and sequencing.

Rationale: The paper explicitly states the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included individuals who had received antiviral therapy for more than 1 year and had a viral load of ≥1000 copies/ml, indicating treatment failure.

Rationale: The paper explicitly states that the study included individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a retrospective analysis of patients who had received antiviral therapy, but does not indicate that it was a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals who had received antiviral therapy for more than 1 year.

Rationale: The paper explicitly states that the individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the individuals had received antiviral therapy, but does not specify the drug classes.

Rationale: The paper does not provide explicit information on the drug classes received by the individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by the individuals.

Rationale: The paper does not provide explicit information on the specific drugs received by the individuals.

Answer: Not reported
""""""",80
37439411,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions the use of HIV-1 RNA protease/reverse transcriptase sequences from patient samples.

Rationale: The paper explicitly states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from patient samples, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility and does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences are not publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 5982 naïve individuals and 9387 treatment-experienced individuals were included in the study.

Rationale: The paper explicitly states the number of individuals included in the study, indicating that samples were obtained from these individuals.

Answer: 5982 naïve individuals and 9387 treatment-experienced individuals
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Italy.

Rationale: The paper explicitly states that the study was conducted in Italy, indicating that the sequenced samples were obtained from Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2000 to 2020.

Rationale: The paper explicitly states the time frame during which the samples were collected, providing a specific range of years.

Answer: 2000-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, focusing instead on the direct analysis of the plasma RNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 RNA protease/reverse transcriptase sequences were retrieved from patient samples.

Rationale: The paper explicitly states that HIV-1 RNA protease/reverse transcriptase sequences were retrieved, indicating that the protease and reverse transcriptase genes were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used for the viral sequences.

Rationale: The paper does not specify the sequencing method used for the viral sequences.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for the study.

Rationale: The paper specifies that plasma samples were used for the study, indicating the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that genotyping on RNA was performed exclusively in cases of virological failure with detectable viraemia.

Rationale: The paper explicitly states that genotyping was performed in cases of virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial, focusing instead on a real-life setting.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that previous exposure to an NNRTI-based regimen was a predictor for resistance to the class.

Rationale: The paper explicitly states that previous exposure to an NNRTI-based regimen was a predictor for resistance, indicating that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that previous exposure to an NNRTI-based regimen was a predictor for resistance to the class.

Rationale: The paper explicitly states that previous exposure to an NNRTI-based regimen was a predictor for resistance, indicating that the individuals had received NNRTI-based regimens before sample sequencing.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify the exact drugs received by the individuals before sample sequencing.

Rationale: The paper does not specify the exact drugs received by the individuals before sample sequencing.

Answer: Not reported
""""""",84
37495103,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp).

Rationale: The paper describes the collection of plasma samples from patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper states that the study cohort included 271 patients.

Answer: 271
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in the Novosibirsk region, Russia.

Rationale: The paper mentions that the study was conducted in the Novosibirsk region, Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study cohort included patients who visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.

Rationale: The paper mentions that the study cohort included patients who visited the hospital between March 2018 and August 2022.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 PR-RT fragment (1302 bp) was amplified.

Rationale: The paper describes the sequencing of the PR-RT fragment.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).

Rationale: The paper explicitly states that DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 RNA was isolated from 250 µL of plasma.

Rationale: The paper describes the collection of plasma samples from patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that all patients had undetectable viral load (VL) levels for 3--6 months while taking ART with further virological failure.

Rationale: The paper indicates that sequences were obtained from individuals experiencing virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that all patients received first-line ART prior to virological failure.

Rationale: The paper indicates that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients received TDF, 3TC, EFV, DTG, LPV/r, and other ARV drugs.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients received TDF, 3TC, EFV, DTG, LPV/r, ABC, and other ARV drugs.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: TDF, 3TC, EFV, DTG, LPV/r, ABC
""""""",86
37498738,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences obtained from patient samples, specifically from peripheral blood mononuclear cells (PBMCs) of early-treated individuals with HIV.

Rationale: The paper mentions the use of near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing to analyze the HIV-1 reservoir in these participants.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the characterization of the HIV-1 reservoir in early-treated individuals, but it does not discuss in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention depositing the sequences in a public database or making them available for download.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or any other database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 101 individuals participated in the study, but it does not specify how many had samples obtained for HIV sequencing.

Rationale: The paper does not provide a clear answer to this question.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not specify the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the geographic origin of the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not specify the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the time period during which the samples were collected.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing, but it does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near full-length HIV-1 proviral sequences were analyzed.

Rationale: The paper does not specify which HIV genes were sequenced, but it mentions that near full-length sequences were analyzed.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of next-generation sequencing.

Rationale: The paper describes the use of near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing.

Answer: Next-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that peripheral blood mononuclear cells (PBMCs) were used for sequencing.

Rationale: The paper describes the use of PBMCs for the analysis of the HIV-1 reservoir.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV-1 sequences from early-treated individuals who were switched to dolutegravir monotherapy.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a randomized clinical trial.

Rationale: The paper describes the study design and the participants, and it mentions that the study was a randomized clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the participants had previously received antiretroviral therapy (ART).

Rationale: The paper describes the study design and the participants, and it mentions that the participants had previously received ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drug classes received by the participants before the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs received by the participants before the study.

Answer: Not reported
""""""",80
37515095,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper explicitly states that HIV-1 sequences were obtained from patient samples, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the analysis of HIV-1 sequences and drug resistance mutations, but it does not detail laboratory-based experiments measuring the effectiveness of drugs against HIV-1 in vitro.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were deposited in GenBank or made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper states that 968 HIV-1 sequences were collected from PLHIV in Kazakhstan.

Answer: 968
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper specifies that the samples were obtained from Kazakhstan.

Answer: Kazakhstan
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper specifies that the samples were collected between 2017 and 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not provide any information regarding the cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper mentions that the sequence data consisted of partial HIV-1 *pol* gene sequences.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper analyzed 968 partial HIV-1 *pol* sequences that were collected between 2017 and 2020 from PLHIV in Kazakhstan.

Rationale: The paper does not specify the type of clinical specimens sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information regarding virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information regarding a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the participants were on prolonged ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions various antiretroviral drugs that belong to NRTI, NNRTI, and PI classes.

Rationale: The paper mentions specific drug classes that were administered to the participants.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions specific drugs such as FTC, TDF, and EFV.

Rationale: The paper mentions specific drugs that were administered to the participants.

Answer: FTC, TDF, EFV
""""""",81
37515146,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients and the extraction of viral RNA, which indicates that HIV sequences were obtained from these patient samples.

Rationale: The paper mentions that viral RNA was extracted from plasma samples and used for genotypic resistance testing, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper discusses the identification of drug resistance mutations and their correlation with treatment regimens, but it does not provide specific in vitro drug susceptibility data.

Rationale: The paper focuses on the prevalence of pre-treatment HIV drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, indicating that these sequences were made publicly available.

Rationale: The paper explicitly states that the sequences are available on GenBank under the accession numbers MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides specific GenBank accession numbers for the sequenced HIV isolates, which are MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates.

Answer: MK702015-MK702057, MK867695-MK867757, MK995397-MK995457
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 379 participants had sequencing successfully carried out, giving a genotyping success rate of 96.9%.

Rationale: The paper mentions that 379 participants had sequencing successfully carried out.

Answer: 379
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper indicates that the samples were obtained from patients in Cameroon.

Rationale: The paper focuses on the HIV-1 genetic diversity of infected individuals in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2014 to 2019.

Rationale: The paper states that the study was conducted from 2014 to 2019.

Answer: 2014-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the extraction of viral RNA from plasma samples and the use of a genotyping assay, but it does not mention any cloning of samples.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease and reverse transcriptase regions of the HIV-1 pol gene were genotyped.

Rationale: The paper specifies that the protease and reverse transcriptase regions of the HIV-1 pol gene were genotyped.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that sequencing was performed using a genetic analyzer (ABI 3500).

Rationale: The paper mentions that sequencing was performed using a genetic analyzer (ABI 3500), which indicates Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper describes the collection of plasma samples from HIV-positive patients.

Rationale: The paper mentions that plasma samples were collected from HIV-positive patients and used for genotypic resistance testing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not specifically mention virological failure.

Rationale: The paper focuses on the prevalence of pre-treatment HIV drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a cross-sectional study conducted at health facilities in Cameroon, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not specifically mention previous ARV drug use.

Rationale: The paper focuses on the prevalence of pre-treatment HIV drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention previous ARV drug use.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not specifically mention the drug classes received before sample sequencing.

Rationale: The paper focuses on the prevalence of pre-treatment HIV drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention the drug classes received before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included patients who were initiating ART, but it does not specifically mention the drugs received before sample sequencing.

Rationale: The paper focuses on the prevalence of pre-treatment HIV drug resistance and the genetic analysis of HIV-1 sequences from patient samples, but it does not mention the drugs received before sample sequencing.

Answer: Not reported
""""""",93
37520425,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotypic resistance testing (GRT) was performed from biobanked samples for those with an HIV VL ≥50 copies/mL.

Rationale: The paper describes the use of genotypic resistance testing to identify HIV-1 drug resistance-associated mutations in patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the virological outcomes of patients on DTG-based and NNRTI-based ART, and does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the reported protease and reverse transcriptase sequences are available in GenBank (accession number OQ627458-OQ627474).

Rationale: The paper provides the GenBank accession numbers for the sequences, indicating that they are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the reported protease and reverse transcriptase sequences are available in GenBank (accession number OQ627458-OQ627474).

Rationale: The paper provides the GenBank accession numbers for the sequences.

Answer: OQ627458-OQ627474
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that blood plasma samples prior to treatment initiation were available for 25 of 30 patients.

Rationale: The paper describes the number of patients for whom samples were available for sequencing.

Answer: 25
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Tanzania.

Rationale: The paper describes the location of the study, indicating that the samples were obtained from Tanzania.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between 2016 and 2020.

Rationale: The paper describes the time period during which the study was conducted, indicating that the samples were obtained during this time.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not describe any cloning procedures, indicating that the samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 genotypic resistance testing (GRT) was performed to determine the HIV-1 drug resistance-associated mutations for reverse transcriptase, protease, and INSTI.

Rationale: The paper describes the genes that were sequenced to identify drug resistance mutations.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that standard Sanger sequencing was used for genotypic resistance testing.

Rationale: The paper describes the sequencing method used to identify drug resistance mutations.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood plasma samples were used for sequencing.

Rationale: The paper describes the type of samples used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that HIV-1 genotypic resistance testing (GRT) was performed for those with an HIV VL ≥50 copies/mL.

Rationale: The paper describes the use of genotypic resistance testing to identify drug resistance mutations in individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a prospective cohort study, indicating that it is not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included treatment-naive patients.

Rationale: The paper describes the study population as treatment-naive, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included treatment-naive patients.

Rationale: The paper describes the study population as treatment-naive, indicating that they had not previously received ARV drugs.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included treatment-naive patients.

Rationale: The paper describes the study population as treatment-naive, indicating that they had not previously received ARV drugs.

Answer: None
""""""",81
37537871,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 proviral sequences from patient samples, specifically from persistent controllers (PCs) and transient controllers (TCs).

Rationale: The paper mentions the use of next-generation sequencing techniques to characterize the HIV-1 reservoir from peripheral blood mononuclear cells (PBMCs) of these patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or results related to in vitro drug susceptibility testing.

Rationale: The focus is on RNA-Seq of HIV-2 genomes from patient plasma samples and lab-adapted strains, and there is no discussion of drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples were collected from 27 elite controllers (ECs), and next-generation sequencing (NGS) was performed on peripheral blood mononuclear cells (PBMC).

Rationale: The paper mentions that samples were collected from 27 elite controllers (ECs).

Answer: 27
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that samples were collected from various hospitals in Spain, Switzerland, and the USA.

Rationale: The paper lists several hospitals in Spain, Lausanne University Hospital in Switzerland, and Massachusetts General Hospital in the USA.

Answer: Spain, Switzerland, USA
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the sequenced samples were obtained.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper describes the use of next-generation sequencing and single proviral genome.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the use of full-length individual proviral sequencing (FLIP-Seq) to analyze the HIV-1 reservoir.

Rationale: This indicates that the full genome of the HIV-1 provirus was sequenced.

Answer: Full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Illumina MiSeq sequencing for the analysis of full-length individual proviral sequences (FLIP-Seq) and integration site analysis (MIP-Seq).

Rationale: The paper mentions the use of Illumina MiSeq sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that peripheral blood mononuclear cells (PBMCs) were used for the characterization of the HIV-1 reservoir and subsequent sequencing.

Rationale: The paper specifies that PBMCs were used for sequencing.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on elite controllers (ECs) who maintain virological control without antiretroviral therapy (ART).

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the collection of samples from elite controllers (ECs).

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drug classes and treatment history were not reported.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads, which means the individuals had received ARV drugs, but the drugs and treatment history were not reported.

Rationale: The paper mentions that the blood samples were collected in a cohort who had suppressed viral loads.

Answer: Not reported
""""""",86
37540331,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples.

Rationale: The paper discusses the efficacy and safety of TAF plus DTG as a new 2DR in HIV-infected patients, but it does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 102 PLWHs were screened for eligibility, of which 17 persons did not meet the inclusion criteria. Finally, 85 patients were randomly assigned to receive TAF plus DTG regimen (n = 43) or to continue the previous 3DR (n = 42).

Rationale: The paper mentions that 85 patients were randomly assigned to receive TAF plus DTG regimen or to continue the previous 3DR.

Answer: 85
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years when the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information that would imply cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the exact sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes a randomized non-inferiority open-label controlled trial.

Rationale: The paper explicitly states that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that patients were treatment-experienced.

Rationale: The paper indicates that the patients in the study were treatment-experienced, which implies that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients were treatment-experienced with various drug classes.

Rationale: The paper indicates that the patients in the study were treatment-experienced with various drug classes, including NRTI, NNRTI, PI, and INSTI.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients were treatment-experienced with various drugs.

Rationale: The paper indicates that the patients in the study were treatment-experienced with various drugs, including DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.

Answer: DTG, ABC, 3TC, BIC, TAF, FTC, DRV/r, DTG, TDF, RPV, LPV, AZT, ATV, EFV, EVG, BIC, DRV/c.
""""""",84
37541705,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study evaluated the pharmacokinetics, safety, and tolerability of once-daily dispersible and immediate-release FDC abacavir/dolutegravir/lamivudine in young children with HIV.

Rationale: The paper does not explicitly mention the reporting of HIV sequences from patient samples. It focuses on the clinical outcomes of the FDC treatment in children with HIV.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention any publicly available sequences or accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 57 participants were enrolled and initiated study drug.

Rationale: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing, but it mentions that 57 participants were enrolled.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were recruited from study sites in Botswana, South Africa, Thailand, and the U.S.

Rationale: The paper does not explicitly mention the countries from which the sequenced samples were obtained, but it mentions the countries where the study sites were located.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled from September 9, 2020 through June 28, 2021.

Rationale: The paper does not explicitly mention the years from which the sequenced samples were obtained, but it mentions the enrollment period.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: There is no reference to cloning in the methods or results sections of the paper.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the sequencing of HIV genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any specific sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention any specific type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that one participant did not achieve virologic suppression at Week 24 and subsequently met the protocol definition of virologic failure.

Rationale: The paper does not explicitly mention the sequencing of individuals with virological failure, but it mentions that one participant met the protocol definition of virologic failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was an international phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper clearly states that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most participants were treatment-experienced at entry and switched from a regimen containing lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the sequencing of individuals who had previously received ARV drugs, but it mentions that most participants were treatment-experienced.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the drug classes received by individuals before sample sequencing, but it mentions the specific drugs.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received lopinavir/ritonavir, dolutegravir, or raltegravir as the anchor medication.

Rationale: The paper does not explicitly mention the drugs received by individuals before sample sequencing, but it mentions the specific drugs.

Answer: Not reported
""""""",84
37546367,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that plasma samples with low-level viral load during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, detailing the methods used for sequencing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of HIV-1 sequences and drug resistance mutations, but it does not include any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The partial pol nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides specific accession numbers for the sequenced HIV isolates, indicating that they were submitted to GenBank and made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The partial pol nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.

Rationale: The paper provides specific accession numbers for the sequenced HIV isolates.

Answer: OQ886077 - OQ888150
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 3274 patients were enrolled and 2074 HIV-1 partial pol sequences were obtained and subsequently used to establish the dataset.

Rationale: The paper states that 2074 HIV-1 partial pol sequences were obtained from 3274 patients.

Answer: 2074
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected from patients living in Guangdong China.

Rationale: The paper explicitly states that the samples were obtained from patients in Guangdong, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected from patients living in Guangdong China between Nov 1st, 2011 to Dec 31st, 2022.

Rationale: The paper explicitly states that the samples were obtained from patients between 2011 and 2022.

Answer: 2011-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of ultracentrifugation to concentrate HIV RNA and Sanger sequencing, but it does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the partial HIV-1 pol gene (HXB2 nt 2253--3252) was amplified by one-step RT-PCR and nested PCR.

Rationale: The paper explicitly states that the partial HIV-1 pol gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the Sanger sequencing was used for the sequencing of the PCR products.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples with low-level viral load during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study focused on patients who had received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.

Rationale: The paper does not explicitly state that the sequences were obtained from individuals with virological failure, but it does mention that the patients had received ART and had a low viral load.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a retrospective study and does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study focused on patients who had received ART for at least 6 months.

Rationale: The paper explicitly states that the patients had received ART, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the initial treatment regimen was 2NRTI+PI or 2NRTI+NNRTI.

Rationale: The paper explicitly states that the patients received NRTI and PI or NNRTI as part of their initial treatment regimen.

Answer: NRTI, PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the initial treatment regimen was 2NRTI+PI or 2NRTI+NNRTI.

Rationale: The paper explicitly states that the patients received NRTI and PI or NNRTI as part of their initial treatment regimen, but it does not specify the exact drugs.

Answer: Not reported
""""""",90
37554471,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",53
37573167,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-DNA was obtained from whole-blood or lymphomonocytic cells after separation from peripheral blood from HIV-1-infected patients.

Rationale: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples, indicating that HIV sequences were obtained from these samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the analysis of resistance mutations and virological data without mentioning specific in vitro drug susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences are not publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 1126 HIV-1 drug-experienced virologically suppressed subjects were included in the study.

Rationale: The paper states that 1126 individuals were included in the study, and HIV-DNA GRT was performed for routine clinical practice.

Answer: 1126
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Italy.

Rationale: The paper states that the study was conducted in several reference centers in Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted over the period 2010-2021.

Rationale: The paper states that the study was conducted from 2010 to 2021.

Answer: 2010-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, focusing instead on the direct analysis of the HIV-DNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that Sanger sequencing was performed for protease, reverse transcriptase (RT), and integrase genes.

Rationale: The paper states that Sanger sequencing was performed for the protease, reverse transcriptase (RT), and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was performed.

Rationale: The paper states that Sanger sequencing was performed for the protease, reverse transcriptase (RT), and integrase genes.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-DNA was obtained from whole-blood or lymphomonocytic cells after separation from peripheral blood from HIV-1-infected patients.

Rationale: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples, indicating that HIV-DNA was sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that individuals were under virological suppression for a median (IQR) of 3.7 (0.3-8.0) years.

Rationale: The paper states that individuals were virologically suppressed, indicating that sequences were not obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial, focusing instead on a retrospective study of drug resistance.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that individuals were drug-experienced and had previously received antiretroviral therapy.

Rationale: The paper states that individuals were drug-experienced and had previously received antiretroviral therapy, indicating that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals received various antiretroviral drugs from different classes, including NRTI, NNRTI, PI, and INSTI.

Rationale: The paper lists various antiretroviral drugs from different classes that were received by the individuals before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals received various antiretroviral drugs, including 3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, and TDF.

Rationale: The paper lists specific antiretroviral drugs that were received by the individuals before sample sequencing.

Answer: 3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF
""""""",89
37574435,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL and were switched to either dolutegravir combined with 2 NRTIs or BIC/FTC/TAF.""

Rationale: The paper mentions that the study included PWH who had viral rebound with plasma HIV RNA >1000 copies/mL, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that 79 PWH were included in the study.

Answer: 79
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not specify the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""No evidence""

Rationale: The paper does not specify the exact years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""No evidence""

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""No evidence""

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""We retrospectively reviewed the medical records of PWH who had viral rebound with plasma HIV RNA >1000 copies/mL and were switched to either dolutegravir combined with 2 NRTIs or BIC/FTC/TAF.""

Rationale: The paper mentions that plasma HIV RNA was analyzed, indicating that the samples were from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""This was a single-center, retrospective cohort study conducted in the National Taiwan University Hospital (NTUH).""

Rationale: The paper mentions that the study was a retrospective cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Seventy-nine PWH with viral rebound while receiving other antiretroviral regimens were included.""

Rationale: The paper mentions that the study included PWH who had viral rebound while receiving other antiretroviral regimens, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most of the patients (70.7%) switched from a previous combination that included two nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transcriptase inhibitor (INSTI) (63.7% DTG).""

Rationale: The paper mentions that patients switched from combinations that included NRTIs and INSTIs.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Most of the patients (70.7%) switched from a previous combination that included two nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transcriptase inhibitor (INSTI) (63.7% DTG).""

Rationale: The paper mentions that patients switched from combinations that included NRTIs and INSTIs, specifically DTG.

Answer: Dolutegravir (DTG)
""""""",77
37585352,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS) from 5805 participants.

Rationale: The paper explicitly states that the study analyzed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 proviral DNA sequences and the prevalence of RPV-RAMs, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that HIV-1 sequences are available on request through the PANGEA consortium (www.pangea-hiv.org).

Rationale: The paper explicitly states that the sequences are available on request, indicating that they are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 5805 participants had their HIV-1 proviral DNA sequences generated using next-generation sequencing (NGS).

Rationale: The paper explicitly states that the study analyzed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs from 5805 participants.

Answer: 5805
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Botswana.

Rationale: The paper explicitly states that the study was conducted in Botswana, and all the sequenced samples were obtained from participants in Botswana.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2013 to 2018.

Rationale: The paper explicitly states that the study was conducted from 2013 to 2018, and all the sequenced samples were obtained during this period.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near full-length HIV-1 pol sequences were generated using next-generation sequencing (NGS).

Rationale: The paper explicitly states that the study analyzed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that next-generation sequencing (NGS) was used to generate HIV-1 proviral DNA sequences.

Rationale: The paper explicitly states that NGS was used to generate HIV-1 proviral DNA sequences.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that HIV-1 proviral DNA sequences were generated from proviral DNA.

Rationale: The paper explicitly states that the study analyzed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study only included ART-suppressed individuals and ART-naive individuals, and did not include individuals with virological failure.

Rationale: The paper explicitly states that the study only included ART-suppressed individuals and ART-naive individuals, and did not include individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any clinical trial, and the study appears to be an observational study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 4524 participants were ART-suppressed, indicating that they had previously received ARV drugs.

Rationale: The paper explicitly states that the study included ART-suppressed individuals, who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The paper explicitly states that the most common ART regimens used were EFV/FTC/TDF, 3TC/NVP/ZDV, and 3TC/EFV/ZDV, which include NNRTIs (efavirenz and nevirapine) and NRTIs (emtricitabine, lamivudine, and zidovudine).

Answer: NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV), and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV).

Rationale: The paper explicitly states that the most common ART regimens used were EFV/FTC/TDF, 3TC/NVP/ZDV, and 3TC/EFV/ZDV, which include efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, and zidovudine.

Answer: Efavirenz, emtricitabine, lamivudine, nevirapine, tenofovir, zidovudine
""""""",104
37593123,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly states that HIV-1 *pol* gene region sequences were obtained from ART-naïve HIV-positive individuals, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that the Stanford HIV Drug Resistance Database was utilized to extrapolate susceptibility to 12 antiretroviral drugs, using the World Health Organization (WHO)'s 2014 HIVDR guidelines as a reference.

Rationale: The paper does not provide experimental results on how effective different drugs are against HIV-1 strains isolated from the studied individuals. Instead, it focuses on analyzing the genetic sequences and clinical parameters like CD4+ T cell counts and viral load to understand the epidemiological and genetic characteristics of HIV-1 in the studied population.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory.

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it mentions that the sequences were obtained from publicly available databases.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The study population consisted of 57,902 ART-naïve HIV-infected individuals.

Rationale: The paper explicitly states that the study population consisted of 57,902 ART-naïve HIV-infected individuals.

Answer: 57,902
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in China.

Rationale: The paper explicitly states that the study was conducted in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the sequences were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.

Rationale: The paper explicitly states that the sequences were obtained from ART-naïve HIV-positive individuals between 2004 and 2022.

Answer: 2004--2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that this information is not provided.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals.

Rationale: The paper explicitly states that the HIV-1 *pol* gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the Stanford HIV Drug Resistance Database was utilized to extrapolate susceptibility to 12 antiretroviral drugs.

Rationale: The paper does not explicitly state the sequencing method used, but it mentions the use of the Stanford HIV Drug Resistance Database.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were prepared at the National HIV Reference Laboratory.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study population consisted of ART-naïve HIV-infected individuals.

Rationale: The paper explicitly states that the study population consisted of ART-naïve HIV-infected individuals, meaning that the participants had not previously received antiretroviral therapy, and therefore, there would be no sequences from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about the patients being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study population consisted of ART-naïve HIV-infected individuals.

Rationale: The paper explicitly states that the study population consisted of ART-naïve HIV-infected individuals, meaning that the participants had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the Stanford HIV Drug Resistance Database was utilized to extrapolate susceptibility to 12 antiretroviral drugs.

Rationale: The paper does not explicitly state the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the Stanford HIV Drug Resistance Database was utilized to extrapolate susceptibility to 12 antiretroviral drugs.

Rationale: The paper does not explicitly state the drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",90
37626789,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that HIV-1 genotyping and sequencing was performed for the pol gene region, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 551 HIV-positive children (<15 years old) were recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper states that 551 HIV-positive children were recruited for the study.

Answer: 551
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""The study was conducted among HIV-infected children taking first-line antiretroviral therapy in Ethiopia.""

Rationale: The paper mentions that the study was conducted in Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""The disease progression of HIV-infected children was retrospectively retrieved for 12 years (2007--2019) and measured as a change in immunosuppression (i.e., CD4 count).""

Rationale: The paper mentions that the disease progression was retrospectively retrieved for 12 years (2007--2019).

Answer: 2007-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that the pol gene region was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""HIV-1 genotyping and sequencing was performed for the pol gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper mentions that an in-house assay validated at the Chinese Center for Disease Control and Prevention was used for sequencing.

Answer: In-house assay
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Whole blood was collected from children using two ethylenediaminetetraacetic acid (EDTA) coated test tubes of 3--5 mL each, and plasma was extracted using centrifugation at 2000 revolutions per minute (RPM).""

Rationale: The paper mentions that whole blood was collected and plasma was extracted for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Children with VF (i.e., viral load ≥ 1000 copies/mL) were included for HIV drug resistance investigation, given those with VL < 1000 copies/mL were considered as susceptible and excluded from HIVDR testing.""

Rationale: The paper mentions that children with virological failure (VF) were included for HIV drug resistance investigation.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper describes the study as a longitudinal study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The study was conducted among HIV-infected children taking first-line antiretroviral therapy in Ethiopia.""

Rationale: The paper mentions that the study was conducted among HIV-infected children taking first-line antiretroviral therapy, which means they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""A majority of the children (80%) were taking one of the three HAARTs regimens, which were Zidovudine (AZT) + Lamivudine(3TC) +Nevirapine (NVP) (35.9%), Stavudine(D4T) + Lamivudine(3TC) + Nevirapine (NVP) (30.3%), and Zidovudine (AZT) + Lamivudine(3TC) + Efavirenz (EFV) (14.0%).""

Rationale: The paper mentions that the children were taking HAARTs regimens that included NRTIs (Zidovudine, Lamivudine, Stavudine) and NNRTIs (Nevirapine, Efavirenz).

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""A majority of the children (80%) were taking one of the three HAARTs regimens, which were Zidovudine (AZT) + Lamivudine(3TC) +Nevirapine (NVP) (35.9%), Stavudine(D4T) + Lamivudine(3TC) + Nevirapine (NVP) (30.3%), and Zidovudine (AZT) + Lamivudine(3TC) + Efavirenz (EFV) (14.0%).""

Rationale: The paper mentions that the children were taking HAARTs regimens that included Zidovudine (AZT), Lamivudine (3TC), Stavudine (D4T), Nevirapine (NVP), and Efavirenz (EFV).

Answer: Zidovudine (AZT), Lamivudine (3TC), Stavudine (D4T), Nevirapine (NVP), Efavirenz (EFV)
""""""",113
37632026,"Here are the answers to the questions in the required format:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""759 patients (≥15 years) experiencing virological failure"" were included in the study and that ""genotypic resistance testing"" was performed on these patients.

Rationale: The paper describes a study that included patients who experienced virological failure and underwent genotypic resistance testing, which involves analyzing HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and the identification of drug resistance mutations, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""Sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958.""

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that ""Sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958.""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""759 patients (≥15 years) experiencing virological failure"" were included in the study.

Rationale: The paper describes a study that included 759 patients who experienced virological failure and underwent HIV sequencing.

Answer: 759
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper explicitly states that the study was conducted in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from November 2011 to August 2019.

Rationale: The paper provides the time period during which the study was conducted.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the extraction of viral RNA from plasma samples and the amplification of the HIV-1 pol gene using PCR, but it does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 pol gene (protease and reverse-transcriptase regions) was amplified and sequenced.

Rationale: The paper explicitly states that the HIV-1 pol gene was sequenced.

Answer: pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that sequencing was performed using an Applied Biosystems 3500 genetic analyzer.

Rationale: The paper provides the specific sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included patients who experienced virological failure on a treatment regimen.

Rationale: The paper describes a study that included patients who experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a laboratory-based cross-sectional and analytical study, but it does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included patients who had previously received ARV drugs.

Rationale: The paper describes a study that included patients who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received NNRTI-based first-line ART regimens and PI/r-based second-line ART regimens.

Rationale: The paper provides the specific drug classes that the patients had received before sample sequencing.

Answer: NNRTI, PI/r
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received specific drugs such as efavirenz (EFV), nevirapine (NVP), zidovudine (AZT), lamivudine (3TC), and tenofovir (TDF).

Rationale: The paper provides the specific drugs that the patients had received before sample sequencing.

Answer: EFV, NVP, AZT, 3TC, TDF
""""""",90
37632071,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it discusses the analysis of plasma HIV RNA and CD4+ cell count in patients living with HIV.

Rationale: The paper focuses on the virological response to the antiretroviral therapy regimen BIC/FTC/TAF in treatment-experienced patients, but it does not explicitly mention the analysis of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or related experiments.

Rationale: The paper focuses on the clinical response to the antiretroviral therapy regimen BIC/FTC/TAF in treatment-experienced patients, but it does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making sequences publicly available.

Rationale: The paper does not mention whether any sequences were made publicly available, as it does not report on any sequencing data.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates, nor does it mention any sequencing data.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses the analysis of plasma HIV RNA and CD4+ cell count in patients living with HIV, but it does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained, as it does not report on any sequencing data.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained, as it does not report on any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not report on any sequencing data or methods, including cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention any specific HIV genes that were sequenced.

Rationale: The paper does not report on any sequencing data or methods, including which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention any sequencing method.

Rationale: The paper does not report on any sequencing data or methods, including the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention any specific type of samples that were sequenced.

Rationale: The paper does not report on any sequencing data or methods, including the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses the analysis of plasma HIV RNA and CD4+ cell count in patients living with HIV, but it does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a retrospective cohort study, but it does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention any HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper discusses the analysis of plasma HIV RNA and CD4+ cell count in patients living with HIV, but it does not mention any HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drug classes that were received by individuals in the study before sample sequencing.

Rationale: The paper does not report on any sequencing data or methods, including the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs that were received by individuals in the study before sample sequencing.

Rationale: The paper does not report on any sequencing data or methods, including the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",84
37649807,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not provide any information regarding in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information about previous ARV drug use.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",54
37662576,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on laboratory-generated recombinant enzymes and mutations in integrase proteins from different HIV subtypes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs received by the individuals in the study before sample sequencing.

Answer: Not reported
""""""",58
37674678,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 *pol* gene sequence was obtained by viral RNA extraction and nested PCR amplification from 1,393 ART-naïve individuals newly diagnosed with HIV-1.

Rationale: The paper specifically focuses on ART-naive individuals, meaning that the participants had not previously received antiretroviral drugs, and it mentions that HIV-1 *pol* gene sequence was obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper does not provide any information about in vitro drug susceptibility testing or data, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that this information is not available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study.

Rationale: The paper states that 1,393 participants were enrolled in the study, and their samples were used for HIV sequencing.

Answer: 1393
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in Nanjing, China.

Rationale: The paper mentions that the study was conducted in Nanjing, China, indicating that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were collected between January 2019 and December 2021.

Rationale: The paper mentions that the samples were collected between January 2019 and December 2021.

Answer: 2019-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not provide any information about cloning samples prior to sequencing, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 *pol* gene sequence was obtained by viral RNA extraction and nested PCR amplification.

Rationale: The paper specifically mentions that the HIV-1 *pol* gene sequence was obtained from the participants.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the PCR products were sent to Sangon Biotechnology Co., Ltd. for automatic DNA sequencing using ABI 3730XL.

Rationale: The paper mentions the use of ABI 3730XL, which is associated with Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were collected and used for viral RNA extraction.

Rationale: The paper specifically mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper specifically focuses on ART-naive individuals, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper does not mention any sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, indicating that this information is not available.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifically focuses on ART-naive individuals, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper does not mention any sequences obtained from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals in the study before sample sequencing, indicating that this information is not available.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about drugs received by individuals in the study before sample sequencing, indicating that this information is not available.

Answer: nan
""""""",82
37701387,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any experiments or results related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information on whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the drug classes received by the individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the specific drugs received by the individuals before sample sequencing.

Answer: Not reported
""""""",55
37716367,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the paper reports HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the paper reports in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the sequences from the paper were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the number of individuals who had samples obtained for HIV sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the samples were cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding which HIV genes were reported to have been sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the patients in the study were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding whether the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide any information regarding which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",56
37755428,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses a case report involving a perinatally HIV-infected infant and mentions that nucleic acids were extracted from remnant dried blood spot specimens collected at the time of HIV diagnosis and sequenced using a Sanger-based method.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from dried blood spot specimens collected at the time of HIV diagnosis.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of HIV drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information on whether the sequences were made publicly available.

Rationale: The paper does not mention depositing the sequences in a public database or providing access to the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or providing accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 143 infants had remnant specimens available for HIVDR testing.

Rationale: The paper specifies that 143 infants had samples available for HIVDR testing, which includes HIV sequencing.

Answer: 143
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected in Haiti.

Rationale: The paper explicitly states that the samples were collected in Haiti as part of a national survey.

Answer: Haiti
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were collected between April 2020 and March 2021.

Rationale: The paper specifies the time period during which the samples were collected.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease/reverse transcriptase (PR/RT) and integrase regions were sequenced.

Rationale: The paper specifies that the PR/RT and integrase regions were sequenced to detect HIV drug resistance mutations.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that a Sanger-based method was used for sequencing.

Rationale: The paper specifies that a Sanger-based method was used to sequence the HIV genes.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spot specimens were used for sequencing.

Rationale: The paper specifies that dried blood spot specimens were used as the source of nucleic acids for sequencing.

Answer: DBS
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any virological failure on a treatment regimen.

Rationale: The paper does not provide any information on virological failure or treatment regimens.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trial involvement.

Rationale: The paper does not provide any information on clinical trial participation.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that most mothers had received DTG-based ART and most infants had been breastfed or were breastfeeding at the time of specimen collection.

Rationale: The paper indicates that the infants were exposed to ARV drugs through their mothers, but it does not provide information on whether the infants themselves had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most mothers had received DTG-based ART.

Rationale: The paper specifies that the mothers had received DTG-based ART, which includes INSTI.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that most mothers had received DTG-based ART.

Rationale: The paper specifies that the mothers had received DTG-based ART, which includes DTG.

Answer: Dolutegravir (DTG)
""""""",74
37775947,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper discusses the analysis of HIV sequences from patient samples using next-generation sequencing (NGS).

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and the impact of pre-existing drug resistance on treatment failure, but it does not include any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention any GenBank accession numbers or public databases where the sequences can be accessed.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers or public databases where the sequences can be accessed.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Overall, of the 1819 participants with NGS data at the ≥200 read depth, 1380 (76%) who started ART with three or more drugs, either in the immediate or the deferred arm, and had virological follow-up of ≥1 month were included in this analysis.""

Rationale: The paper states that 1380 participants had samples obtained for HIV sequencing.

Answer: 1380
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that ""Participants in Africa and the USA appeared to be more likely to have a GSS = 3 (chi-squared *p* \< 0.001).""

Rationale: The paper does not provide a comprehensive list of countries, but it mentions Africa and the USA as regions with a higher likelihood of having a GSS = 3.

Answer: Africa, USA
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper states that the samples were obtained from participants enrolled in the START trial between 2009 and 2013.

Answer: 2009-2013
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of next-generation sequencing (NGS) and the analysis of viral RNA, but it does not mention any cloning steps.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""Sequence reads (FASTQ files) were analyzed with VirVarSeq version 20140929, which calls variants at the codon level \[ 27 \]. From the output, we extracted amino acid frequencies in the *pol* gene from amino acid position 1--935 where positions 1--99 encode protease protein, positions 100--659 encode reverse transcriptase protein, and positions 660--935 partially encode integrase protein (our amplicon did not cover positions 936--947) \[ 25 \].""

Rationale: The paper mentions that the *pol* gene was sequenced, which includes the protease, reverse transcriptase, and integrase proteins.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper states that next-generation sequencing (NGS) using the Illumina MiSeq platform was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq).""

Rationale: The paper states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""The primary endpoint of this analysis was treatment failure (TF), a composite outcome defined at the time of two possible failure events: (1) the time of experiencing a single plasma HIV RNA \>200 copies/mL after \>6 months of therapy initiation if this event was followed by a change of one or more drugs (including discontinuation) of the regimen received at time of the elevated HIV RNA value or (2) the time of pure confirmed VF, defined at the time of the first of two consecutive HIV-RNA viral loads \>200 copies/mL.""

Rationale: The paper focuses on treatment failure and virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper states that the study was a clinical trial, specifically the START trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper states that the participants were ART-naïve, meaning they had not previously received antiretroviral drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""First-line ART included a non-nucleoside reverse transcriptase inhibitor (NNRTI) in 976 (71%), a boosted protease inhibitor in 297 (22%), or an integrase strand transfer inhibitor in 107 (8%).""

Rationale: The paper states that the participants received NNRTI, PI, and INSTI drug classes as part of their first-line ART regimen.

Answer: NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that ""First-line ART included a non-nucleoside reverse transcriptase inhibitor (NNRTI) in 976 (71%), a boosted protease inhibitor in 297 (22%), or an integrase strand transfer inhibitor in 107 (8%).""

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study.

Answer: Not reported
""""""",111
37817087,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and integrase (IN) sequences were obtained from 3097 (26.9%) cases.""

Rationale: The paper explicitly states that sequences were obtained from patient samples, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility data or phenotypic data. It mentions clinical isolates and sequencing of plasma samples.

Rationale: The paper does not provide any information about in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention that the sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and integrase (IN) sequences were obtained from 3097 (26.9%) cases.""

Rationale: The paper states that samples were obtained from 4559 cases for PR and RT sequencing, and from 3097 cases for PR, RT, and IN sequencing.

Answer: 4559
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Germany.

Rationale: The paper explicitly states that the samples were obtained from Germany.

Answer: Germany
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from 2017 to 2020.

Rationale: The paper explicitly states that the samples were obtained from 2017 to 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease (PR), reverse-transcriptase (RT), and integrase (IN) genes were sequenced.

Rationale: The paper explicitly states that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that the sequences were obtained using an Illumina NGS method (MiSeq).

Rationale: The paper explicitly states that the Illumina NGS method (MiSeq) was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma or serum samples were sequenced.

Rationale: The paper explicitly states that plasma or serum samples were sequenced.

Answer: Plasma; Serum
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not explicitly mention that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals had previously received ARV drugs.

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals had previously received NRTIs, NNRTIs, PIs, and INIs.

Rationale: The paper explicitly states that some individuals had previously received these drug classes.

Answer: NRTI, NNRTI, PI, INI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some individuals had previously received TDF, FTC, 3TC, ABC, and other drugs.

Rationale: The paper explicitly states that some individuals had previously received these drugs.

Answer: Tenofovir disoproxil fumarate (TDF), Emtricitabine (FTC), Lamivudine (3TC), Abacavir (ABC)
""""""",81
37823653,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, specifically from antiretroviral therapy (ART)-naïve and ART-experienced individuals in Botswana.

Rationale: The paper mentions the use of HIV-1 sequences from patient samples, indicating that the sequences were derived from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility and does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences may not be publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 6,078 HIV-1 near full length sequences were generated for the BCPP study.

Rationale: The paper mentions that a total of 6,078 HIV-1 near full length sequences were generated for the BCPP study, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 6,078
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples in Botswana.

Rationale: The paper mentions that the study was conducted in Botswana, indicating the country from which the sequenced samples were obtained.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the sequences were generated from a large HIV-1 population-based cohort enrolled between 2013 and 2018.

Rationale: The paper provides the years during which the samples were collected, indicating the time frame of the study.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, indicating that the samples were not cloned.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, specifically the gp120 fragment of the HIV envelope gene.

Rationale: The paper mentions the use of the gp120 fragment of the HIV envelope gene, indicating the specific gene sequenced.

Answer: gp120
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of next-generation sequencing (NGS) on the Illumina platform.

Rationale: The paper specifies the use of NGS on the Illumina platform, indicating the sequencing method used.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions the use of plasma samples for sequencing.

Rationale: The paper specifies the use of plasma samples, indicating the type of clinical specimens sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the analysis of sequences from individuals experiencing virological failure (VF) on ART.

Rationale: The paper mentions the analysis of sequences from individuals experiencing VF on ART, indicating that sequences were obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention any clinical trial, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions the inclusion of individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study, indicating that the drug classes are not reported.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study.

Rationale: The paper does not provide specific names of the drugs received by the individuals in the study, indicating that the drugs are not reported.

Answer: Not reported
""""""",82
37872202,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates. This is an in vitro paper  focusing on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify the number of individuals from whom samples were obtained for HIV sequencing. It focuses on the methodology and results of the sequencing study.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper focuses on the integrase (IN) gene of HIV-1, particularly examining mutations and their effects on drug resistance and enzyme activity.

Rationale: The paper discusses the sequencing of the integrase (IN) gene of HIV-1.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention any experiments or data related to virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention that the patients had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",65
37878637,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA was extracted from plasma and full-length cDNA synthesized as described previously. A total of 29 adult subjects recruited between 2006 and 2011 in Uganda and whose plasma was collected during the acute/early phase of HIV-1 infection were analyzed in this study.

Rationale: The paper reports the sequencing of HIV-1 from patient samples, specifically from plasma collected during the acute/early phase of HIV-1 infection.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the genetic characterization and replication capacity of HIV-1 variants, but there is no mention of testing the susceptibility of these variants to antiretroviral drugs in vitro.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, which suggests that the sequences may not be publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 29 adult subjects recruited between 2006 and 2011 in Uganda and whose plasma was collected during the acute/early phase of HIV-1 infection were analyzed in this study.

Rationale: The paper states that a total of 29 adult subjects were analyzed in the study.

Answer: 29
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper clearly states that the study was conducted in Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2018--2020.

Rationale: The paper explicitly mentions the years during which the study was conducted.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of next-generation sequencing and single proviral genome, but does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that sequencing was conducted on the HIV-1 protease and reverse transcriptase regions.

Rationale: The paper specifies that sequencing was conducted on the HIV-1 protease and reverse transcriptase regions.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper describes the use of next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq).

Rationale: The paper mentions the use of next-generation sequencing techniques, specifically FLIP-Seq and MIP-Seq.

Answer: Next-generation sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples from HIV-1-positive individuals were used for sequencing.

Rationale: The paper mentions that plasma samples from HIV-1-positive individuals were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that among the 28 patients receiving HAART, a significant proportion had resistance to NRTIs and NNRTIs, indicating virological failure.

Rationale: The paper mentions that among the 28 patients receiving HAART, a significant proportion had resistance to NRTIs and NNRTIs, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that among the 28 patients receiving HAART, a significant proportion had resistance to NRTIs and NNRTIs, indicating that these individuals had previously received ARV drugs.

Rationale: The paper mentions that among the 28 patients receiving HAART, a significant proportion had resistance to NRTIs and NNRTIs, indicating that these individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists the specific drugs that were part of the treatment regimens for the individuals in the study, including lamivudine, stavudine, nevirapine, zidovudine, and efavirenz, which includes both NRTI and NNRTI.

Rationale: The paper lists the specific drugs that were part of the treatment regimens for the individuals in the study, including lamivudine, stavudine, nevirapine, zidovudine, and efavirenz, which includes both NRTI and NNRTI.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists the specific drugs that were part of the treatment regimens for the individuals in the study, including lamivudine, stavudine, nevirapine, zidovudine, and efavirenz.

Rationale: The paper lists the specific drugs that were part of the treatment regimens for the individuals in the study, including lamivudine, stavudine, nevirapine, zidovudine, and efavirenz.

Answer: Lamivudine, Stavudine, Nevirapine, Zidovudine, Efavirenz
""""""",98
37880705,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that it analyzed 1070 HIV-1 pol sequences from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly states that it analyzed HIV-1 pol sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the analysis of HIV-1 pol sequences and the prevalence of drug resistance mutations, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making the sequences publicly available.

Rationale: The paper does not mention depositing the sequences in a public database or making them available for download.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or providing accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that it analyzed 1070 HIV-1 pol sequences from ART-naïve Ethiopian individuals.

Rationale: The paper explicitly states that it analyzed sequences from 1070 individuals.

Answer: 1070
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Ethiopia.

Rationale: The paper explicitly states that the samples were obtained from Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained between 2003 and 2018.

Rationale: The paper explicitly states that the samples were obtained between 2003 and 2018.

Answer: 2003-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that it analyzed HIV-1 pol sequences.

Rationale: The paper explicitly states that it analyzed HIV-1 pol sequences, which includes the protease and reverse transcriptase genes.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not mention the specific sequencing method used, such as Sanger or next-generation sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that it analyzed HIV-1 pol sequences from whole blood specimens.

Rationale: The paper explicitly states that whole blood specimens were used for sequencing.

Answer: Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequencing individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on analyzing sequences from ART-naïve individuals, indicating that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes a prospective HIVDR survey among antiretroviral-naïve adults, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some individuals had prior drug exposure for treating HIV infection.

Rationale: The paper includes individuals who had prior drug exposure for treating HIV infection, indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not mention the specific drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals before sample sequencing.

Rationale: The paper does not mention the specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",73
37896785,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.

Rationale: The paper describes the analysis of HIV-1 sequences from patient samples, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility assays or data.

Rationale: The paper focuses on genotypic resistance testing and the presence of antiretroviral-resistant mutations in patient samples, but does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper explicitly states that the sequences described in the article have been deposited in GenBank.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions that the nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).

Rationale: The paper provides the GenBank accession numbers for the 61 sequences presented in the study.

Answer: OQ215322-OQ215382
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study material was blood plasma samples collected in 2021 from 61 pregnant women.

Rationale: The paper states that 61 pregnant women had samples obtained for HIV sequencing.

Answer: 61
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City, Vietnam.

Rationale: The paper specifies that the samples were collected from pregnant women in Ho Chi Minh City, Vietnam.

Answer: Vietnam
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study material was blood plasma samples collected in 2021.

Rationale: The paper mentions that the samples were collected in 2021.

Answer: 2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of Sanger sequencing and does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 genotyping and mutation detection were performed based on analysis of the nucleotide sequences of the *pol* gene region.

Rationale: The paper mentions that the *pol* gene region was sequenced, which includes the protease and reverse transcriptase genes.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper describes the use of Sanger sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood plasma samples were used for sequencing.

Rationale: The paper specifies that blood plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 31 women showed virological failure of ART.

Rationale: The paper describes sequencing HIV from patients with virological failure of ART.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention any clinical trial.

Rationale: The paper does not describe a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that 31 women showed virological failure of ART.

Rationale: The paper describes sequencing HIV from patients who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common first-line ART regimens in Vietnam comprise two NRTIs and one NNRTI.

Rationale: The paper mentions that the most common first-line ART regimens include NRTIs and NNRTIs.

Answer: NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the most common first-line ART regimens in Vietnam comprise two NRTIs (stavudine (d4T)/lamivudine (3TC) or zidovudine (AZT)/lamivudine) together with one NNRTI (nevirapine (NVP) or efavirenz (EFV)).

Rationale: The paper mentions that the most common first-line ART regimens include specific NRTIs and NNRTIs.

Answer: Stavudine (d4T), Lamivudine (3TC), Zidovudine (AZT), Nevirapine (NVP), Efavirenz (EFV)
""""""",83
37896860,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""A total of 704 children were enrolled in the study with a median age 9 years (interquartile range (IQR) 7, 12); 344 (49%) were female, and the median time on ART was 5 years (IQR 3, 8).""

Rationale: The paper discusses a study involving 704 children with HIV, and it mentions that the children were enrolled in the study and had their viral loads and drug resistance tested.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The DRT result reports contained a list of the DR genotypes as well as phenotypic interpretations based on the scoring systems generated by the Stanford Genotypic Resistance Interpretation Algorithm (Stanford Univeristy, Palo Alto, CA, USA) versions available during the study period [23].""

Rationale: The paper mentions the use of the Stanford Genotypic Resistance Interpretation Algorithm to interpret the drug resistance test results, but it does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""The data of the nucleotide sequences generated and analyzed during the current study are available in the GenBank NCBI""

Rationale: The paper does not explicitly state that the sequences were made publicly available, but it mentions that the data are available in the GenBank NCBI.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""The data of the nucleotide sequences generated and analyzed during the current study are available in the GenBank NCBI""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""A total of 704 children were enrolled in the study""

Rationale: The paper mentions that 704 children were enrolled in the study, but it does not specify how many of them had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""CHIV ages 1--14 years enrolled from March 2019 to December 2020 from five facilities in Kisumu County, Kenya""

Rationale: The paper mentions that the study was conducted in Kenya.

Answer: Kenya
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""CHIV ages 1--14 years enrolled from March 2019 to December 2020""

Rationale: The paper mentions that the study was conducted from March 2019 to December 2020.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories.""

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories. These laboratories utilize validated, WHO-certified, optimized in-house assays to detect reverse transcriptase and PI mutations [21, 22].""

Rationale: The paper mentions that the laboratories used assays to detect reverse transcriptase and PI mutations, indicating that the reverse transcriptase and protease genes were sequenced.

Answer: RT, PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories.""

Rationale: The paper mentions that Sanger sequencing was used for HIV DR testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories.""

Rationale: The paper mentions that plasma samples were used for HIV DR testing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""During the 12-month study period, 190 study DRTs were requested for 106 (15%) participants across the two study groups.""

Rationale: The paper mentions that the study included participants with virological failure, and that drug resistance testing was performed on these participants.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""The Optimizing Viral Suppression in Children on ART in Kenya (Opt4Kids) study protocol and primary findings have been described previously [18, 19].""

Rationale: The paper mentions that the study was a clinical trial, specifically the Opt4Kids study.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""A total of 704 children were enrolled in the study with a median age 9 years (interquartile range (IQR) 7, 12); 344 (49%) were female, and the median time on ART was 5 years (IQR 3, 8).""

Rationale: The paper mentions that the children in the study had been on ART for a median of 5 years, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""First-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older [24].""

Rationale: The paper mentions that the children in the study received ART regimens that included NRTIs (abacavir, zidovudine, lamivudine), PIs (lopinavir/ritonavir), and NNRTIs (efavirenz).

Answer: NRTI, PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""First-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older [24].""

Rationale: The paper mentions that the children in the study received specific ART regimens that included abacavir, zidovudine, lamivudine, lopinavir/ritonavir, and efavirenz.

Answer: Abacavir, Zidovudine, Lamivudine, Lopinavir/ritonavir, Efavirenz
""""""",122
37910452,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not mention making sequences publicly available. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequencing or the number of individuals with samples obtained for sequencing. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention sequenced samples or the countries from which they were obtained. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention sequenced samples or the years from which they were obtained. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or cloning of samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention sequencing of HIV genes. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or the method used for sequencing. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or the type of samples sequenced. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or virological failure on a treatment regimen. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences or ARV drugs. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or drug classes received by individuals. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention sequencing or drugs received by individuals. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Answer: Not reported
""""""",71
37914679,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the sequencing of HIV-1 pol (RT/PR) amplicons from patient samples.

Rationale: The paper mentions that HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020, with drug-sensitive results from traditional pre-existing drug resistance test, were enrolled in this study.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention any specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 76 patients enrolled in this study had been tested for pre-existing resistance by conventional Sanger sequencing at baseline.

Rationale: The paper mentions that 76 patients were enrolled in the study.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention any specific countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the samples were obtained.

Answer: Not Found
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020.

Rationale: The paper mentions the years during which the patients attended the hospital.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper focuses on the direct analysis of the plasma RNA.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the sequencing of the HIV-1 pol gene, specifically the protease (PR) and reverse transcriptase (RT) regions.

Rationale: The paper discusses the sequencing of the HIV-1 pol gene.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of the MiSeq second-generation sequencing platform.

Rationale: The paper specifies that the MiSeq platform was used for sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that plasma samples were used for the study.

Rationale: The paper mentions the use of plasma samples for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper discusses the analysis of samples from patients who experienced virological failure.

Rationale: The paper confirms that sequences were obtained from individuals with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not indicate that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions the inclusion of treatment naïve patients.

Rationale: The paper focuses on antiretroviral-naïve individuals.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not report the drugs being received by the individuals before sample sequencing.

Rationale: The paper focuses on antiretroviral-naïve individuals.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not report the drugs being received by the individuals before sample sequencing.

Rationale: The paper focuses on antiretroviral-naïve individuals.

Answer: Not reported
""""""",71
37920909,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 integrase genes of 601 cases were sequenced successfully.

Rationale: The paper specifically states that HIV-1 integrase genes were sequenced from patient samples, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the HIV-1 integrase genes of 601 cases were sequenced successfully.

Rationale: The paper specifically states that 601 cases were sequenced, indicating that samples from 601 individuals were obtained for HIV sequencing.

Answer: 601
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023.

Rationale: The paper specifically states that the samples were obtained between 2020 and 2023.

Answer: 2020-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV-1 integrase genes of 601 cases were sequenced successfully.

Rationale: The paper specifically states that HIV-1 integrase genes were sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes.

Rationale: The paper specifically states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that 5 mL of blood was collected from the participants.

Rationale: The paper specifically states that blood samples were used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention any virological failure on a treatment regimen.

Rationale: The paper does not provide information on virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information on a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study recruited 629 ART-naïve individuals.

Rationale: The paper specifically states that the individuals were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on drug classes received before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on drugs received before sample sequencing.

Answer: Not reported
""""""",72
37938856,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not provide information on the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not specify the exact sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not provide information on whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not provide information on whether the sequences were from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not provide information on the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",54
37941373,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper clearly states that plasma samples were obtained from HIV-1 patients, indicating that HIV sequences from patient samples were reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""Samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples.""

Rationale: The paper mentions that samples were obtained from 1080 patients, but successful amplification of the IN gene was achieved in 1032 samples.

Answer: 1032
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients at Chongqing Public Health Medical Center in China.

Rationale: The paper clearly states that the samples were obtained from patients in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients at Chongqing Public Health Medical Center from July 2019 to August 2022.

Rationale: The paper clearly states that the samples were obtained from patients between July 2019 and August 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 IN gene was amplified and sequenced.

Rationale: The paper clearly states that the HIV-1 IN gene was amplified and sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger dideoxy sequencing was employed for the identification of the clinically significant known drug resistance mutations.

Rationale: The paper clearly states that Sanger dideoxy sequencing was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were obtained from HIV-1 patients.

Rationale: The paper clearly states that plasma samples were obtained from HIV-1 patients.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some patients had resistance to INSTIs, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients had resistance to INSTIs, indicating that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients had resistance to NNRTIs or NRTIs, indicating that these drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that patients had resistance to RAL, EVG, and DTG, indicating that these drugs were received by individuals in the study before sample sequencing.

Rationale: The paper discusses the presence of drug resistance mutations in patients with treatment, indicating that sequences were obtained from such individuals.

Answer: RAL, EVG, DTG
""""""",81
37946329,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions the analysis of plasma samples derived from people living with HIV (PLWH) in the Sixth People's Hospital of Zhengzhou from June 2018 to April 2022.

Rationale: The paper explicitly mentions the analysis of plasma samples from PLWH, indicating that HIV sequences were obtained from these patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is provided in the paper.

Rationale: The paper focuses on the analysis of drug resistance mutations (DRMs) in patient samples and does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is provided in the paper.

Rationale: The paper does not mention that the sequences were made publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are provided in the paper.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 921 HIV-1 patients were included in the study.

Rationale: The paper explicitly states the number of patients included in the study.

Answer: 921
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The samples were obtained from Henan Province, China.

Rationale: The paper mentions that the samples were derived from people living with HIV (PLWH) in the Sixth People's Hospital of Zhengzhou from June 2018 to April 2022.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The samples were obtained from June 2018 to April 2022.

Rationale: The paper explicitly mentions the time frame during which the samples were collected.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning is provided in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The partial pol gene and complete integrase gene-coding sequences were amplified, sequenced, and analyzed.

Rationale: The paper explicitly mentions the specific genes that were sequenced.

Answer: Pol, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: No specific sequencing method is mentioned in the paper.

Rationale: The paper does not provide any information regarding the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were used for the study.

Rationale: The paper mentions that plasma samples were derived from people living with HIV (PLWH) in the Sixth People's Hospital of Zhengzhou from June 2018 to April 2022.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: Yes, the study included patients who failed in ART treatment.

Rationale: The paper explicitly mentions that the study included patients who failed in ART treatment.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial is provided in the paper.

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: Yes, the study included patients who had previously received ARV drugs.

Rationale: The paper mentions that the patients had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had previously received NRTIs, NNRTIs, PIs, and INSTIs.

Rationale: The paper explicitly mentions the specific drug classes that were received by the patients before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had previously received specific drugs such as 3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, and TDF.

Rationale: The paper explicitly mentions the specific drugs that were received by the patients before sample sequencing.

Answer: 3TC, NVP, EFV, D4T, AZT, LPV, ABC, ATZ, DTG, TDF
""""""",75
37957382,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences obtained from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of five HIV-1-infected individuals.

Rationale: The paper mentions the use of next-generation sequencing techniques to characterize the HIV-1 reservoir from peripheral blood mononuclear cells (PBMCs) of these patients.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the characterization of latent HIV-1 proviruses and their role in viral rebound, but it does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or any other database.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention depositing the sequences in GenBank or any other database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that samples were obtained from 8 individuals with non-suppressible viremia (NSV).

Rationale: The paper focuses on the analysis of HIV-1 sequences obtained from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of these individuals.

Answer: 8
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the geographical location of the study participants.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information on the time period during which the study was conducted.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning the samples prior to sequencing.

Rationale: The paper describes the use of next-generation sequencing techniques, which does not require cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that near-full-length proviral sequences were obtained, which includes the pol-env region.

Rationale: The paper focuses on the analysis of HIV-1 sequences obtained from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of these individuals.

Answer: Near full length genome
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions the use of Illumina sequencing for the analysis of near-full-length proviral sequences.

Rationale: The paper describes the use of next-generation sequencing techniques, which includes Illumina sequencing.

Answer: Illumina sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that CD4+ T cells from peripheral blood and lymph nodes were sequenced.

Rationale: The paper focuses on the analysis of HIV-1 sequences obtained from patient samples, specifically from CD4+ T cells in peripheral blood and lymph nodes of these individuals.

Answer: PBMC, LNMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on individuals with non-suppressible viremia (NSV) who are on antiretroviral therapy (ART) but still have detectable viral loads.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide information on the study design or whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study participants were on antiretroviral therapy (ART) and had previously received ARV drugs.

Rationale: The paper focuses on individuals with non-suppressible viremia (NSV) who are on ART but still have detectable viral loads.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper mentions that the study participants were on ART but does not provide information on the specific drug classes or regimens used.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not specify the drugs received by individuals in the study before sample sequencing.

Rationale: The paper mentions that the study participants were on ART but does not provide information on the specific drugs or regimens used.

Answer: Not reported
""""""",87
37966701,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the sequencing of HIV from patient samples.

Rationale: The paper discusses the use of cabotegravir + rilpivirine long-acting (CAB + RPV LA) injectable for HIV treatment in the US, but it does not provide information about sequencing HIV from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not explicitly mention in vitro drug susceptibility data.

Rationale: The paper discusses the use of cabotegravir + rilpivirine long-acting (CAB + RPV LA) injectable for HIV treatment in the US, but it does not provide information about in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, such as through GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which sequenced samples were obtained.

Rationale: The paper does not provide information about the years from which sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information about cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide information about specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",71
37973713,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-1 sequences from patient samples, including the determination of HIV-1 subtype and the presence of drug resistance mutations.

Rationale: The paper explicitly mentions the analysis of HIV-1 sequences from patient samples, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention conducting in vitro drug susceptibility tests or data related to drug resistance assays in a laboratory setting.

Rationale: The paper focuses on the analysis of drug resistance mutations and their prevalence in patient samples, but it does not mention conducting in vitro drug susceptibility tests.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available or provide any GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention providing GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 117 patients were recruited for the study.

Rationale: The paper explicitly states the number of patients recruited for the study, indicating the number of individuals from whom samples were obtained for sequencing.

Answer: 117
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from patients from Ukraine and Poland.

Rationale: The paper explicitly states the countries of origin for the patients, indicating the countries from which the sequenced samples were obtained.

Answer: Ukraine, Poland
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patients were recruited during a 2-year period (2020-2022).

Rationale: The paper explicitly states the time frame during which the samples were collected, providing a specific range of years.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the HIV-1 protease and reverse transcriptase coding region were sequenced.

Rationale: The paper explicitly states the genes that were sequenced, indicating the specific HIV genes that were analyzed.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used for the analysis of HIV-1 sequences.

Rationale: The paper explicitly states the sequencing method used, indicating that Sanger sequencing was employed.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for the analysis of HIV-1 sequences.

Rationale: The paper explicitly states the type of clinical specimens sequenced, indicating that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that the patients were experiencing virological failure on a treatment regimen.

Rationale: The paper does not indicate that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was registered on clinicaltrials.gov (Number: NCT04636736).

Rationale: The paper explicitly states that the study was registered on clinicaltrials.gov, indicating that the patients were part of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients were ART-experienced.

Rationale: The paper indicates that some patients had previously received ARV drugs, but it does not provide specific information on the sequences obtained from these individuals.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients were ART-experienced, but it does not provide specific information on the drug classes received.

Rationale: The paper indicates that some patients had previously received ARV drugs, but it does not provide specific information on the drug classes received.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that some patients were ART-experienced, but it does not provide specific information on the drugs received.

Rationale: The paper indicates that some patients had previously received ARV drugs, but it does not provide specific information on the specific drugs received.

Answer: Not reported
""""""",79
37976080,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: A total of 2869 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions, thus yielding a final sample size of 2568.

Rationale: The paper mentions that 2568 participants had PDR test results available, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data was found in the paper.

Rationale: The paper focuses on the prevalence of pretreatment HIV drug resistance and the molecular transmission network among HIV-positive individuals in China, but does not mention any in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences was found in the paper.

Rationale: The paper does not mention that the sequences were made publicly available, and no GenBank accession numbers are provided.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers were provided in the paper.

Rationale: The paper does not mention any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: A total of 2869 HIV-positive individuals were initially recruited into the study.

Rationale: The paper mentions that 2869 individuals were initially recruited, but after removal of some individuals, the final sample size was 2568.

Answer: 2568
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The study was conducted in 8 provincial-level administrative divisions in China.

Rationale: The paper mentions that the study was conducted in China, but does not specify the countries.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The study was conducted in 2022.

Rationale: The paper mentions that the study was conducted in 2022.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning was found in the paper.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The HIV pol gene region (HXB2: 2253-3553 nt) was sequenced, covering the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids).

Rationale: The paper mentions that the HIV pol gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: Sanger sequencing was used to sequence the amplified products.

Rationale: The paper mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Plasma samples were used for sequencing.

Rationale: The paper mentions that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of virological failure was found in the paper.

Rationale: The paper does not mention any virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence of a clinical trial was found in the paper.

Rationale: The paper does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: 3.2% (n=81) of participants had prior ARV drug exposure.

Rationale: The paper mentions that some participants had prior ARV drug exposure.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No specific drug classes were mentioned in the paper.

Rationale: The paper does not mention any specific drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No specific drugs were mentioned in the paper.

Rationale: The paper does not mention any specific drugs.

Answer: Not reported
""""""",71
37976185,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the analysis of HIV-DNA sequences obtained from patient samples. Specifically, it mentions that HIV-DNA sequences were obtained from the peripheral blood of six participants over a period of 3 to ≥15 years of effective therapy.

Rationale: The paper mentions that HIV-DNA sequences were obtained from patient samples, indicating that the answer is yes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any experiments or data related to in vitro drug susceptibility testing.

Rationale: The paper focuses on the persistence of HIV in memory CD4+ T-cells and the genetic analysis of HIV-DNA sequences, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any information about the GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that six HIV-1 subtype-B positive individuals on prolonged ART were included in the study.

Rationale: The paper mentions that six individuals had samples obtained for HIV sequencing.

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was approved in Western Sydney Health Department for the Westmead Institute for Medical Research (Australia), and University of California San Francisco (United States), Vaccine Gene Therapy Institute-Florida (United States)

Rationale: The paper mentions that the study was approved in these locations, indicating that the samples were obtained from these countries.

Answer: United States, Australia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide specific years for when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning the samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that single-proviral sequencing (SPS) was used to amplify the gag-pol region of HIV genome (p6-RT).

Rationale: The paper mentions that the gag-pol region of HIV genome was sequenced.

Answer: Gag, PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper describes the use of single-proviral sequencing (SPS) to obtain individual intracellular HIV-DNA sequences from the extracted DNA, but doesn't mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper specifies that CD4+ T-cell subsets were sorted from frozen aliquots of peripheral blood mononuclear cells (PBMCs), and HIV-DNA was sequenced.

Rationale: The paper mentions that CD4+ T-cell subsets from PBMCs were sequenced.

Answer: PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the participants had viral loads of <40-75 copies (HIV-RNA) per ml during the study period, indicating effective viral suppression and not virological failure.

Rationale: The paper does not provide any information about virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals on prolonged ART, indicating that the participants had previously received antiretroviral drugs.

Rationale: The paper mentions that the participants were on prolonged ART.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide any information about the drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific names of the drugs received by the individuals in the study. It only mentions that the participants were on prolonged ART.

Rationale: The paper does not provide any information about the drugs.

Answer: Not reported
""""""",81
37993493,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: ""Viral load testing was performed using Roche cobas 6800/8800 systems with a lower limit of detection of 15 copies/mL. Given that we followed the current Tanzania national HIV treatment guidelines, only samples with viral load count ≥ 1000 copies/mL were subjected to analysis of HIVDR mutations.""

Rationale: The paper mentions that HIVDR mutations were analyzed from patient samples with viral load counts ≥ 1000 copies/mL, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""The detection of high-level resistance against NRTs and NNRTIs was consistent with patients' treatment history. Furthermore, patients with INSTI mutations and high level INSTI resistance (MC-243, MC-367 and CR-048) had a history of using DTG-based regimen.""

Rationale: The paper does not report in vitro drug susceptibility data. Instead, it discusses the detection of high-level resistance against NRTs and NNRTIs based on patients' treatment history and genotypic resistance data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: ""In total 600 individuals participated in this survey... Genetic sequencing was successful in the protease and reverse transcriptase regions for 23 patients' samples (69.70%) and in the integrase region for 30 patients' samples (90.90%).""

Rationale: The paper mentions that 600 individuals participated in the survey, but only 23 and 30 samples were successfully genotyped for the protease and reverse transcriptase regions and the integrase region, respectively.

Answer: 600
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: ""This study aimed at determining the prevalence of viral suppression and HIV drug resistance (HIVDR) among a random sample of 600 HIV treatment-experienced adults (18 years and above) living in Ukonga and Gongolamboto, Dar es Salaam...""

Rationale: The paper mentions that the study was conducted in Dar es Salaam, Tanzania, indicating that the sequenced samples were obtained from Tanzania.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: ""Between February and May 2023 a cross-sectional survey with random sampling was conducted in the six clinics in an urban cohort in Dar es Salaam.""

Rationale: The paper mentions that the survey was conducted between February and May 2023, indicating that the sequenced samples were obtained during this period.

Answer: 2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: ""No evidence""

Rationale: The paper does not provide any information about cloning samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The sequenced codons were 6--99, 1--251, and 1--288, for protease, reverse transcriptase and integrase proteins, respectively.""

Rationale: The paper mentions that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: ""We used Management and Development for Health (MDH) WHO adapted protocol (Unpublished) to perform HIVDR testing using the 3500xL genetic analyser (Applied Biosystems), a capillary sequencer using Sanger-style sequencing.""

Rationale: The paper mentions that Sanger-style sequencing was used for HIVDR testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: ""Viral load testing was performed using Roche cobas 6800/8800 systems with a lower limit of detection of 15 copies/mL. Given that we followed the current Tanzania national HIV treatment guidelines, only samples with viral load count ≥ 1000 copies/mL were subjected to analysis of HIVDR mutations.""

Rationale: The paper mentions that plasma samples with viral load counts ≥ 1000 copies/mL were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Of 33 patients with high viral load (≥ 1000 copies/mL) despite taking ART, 30 (90.91%) were using a DTG-based regimen...""

Rationale: The paper mentions that sequences were obtained from individuals with high viral load (≥ 1000 copies/mL) despite taking ART, indicating virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: ""A cross-sectional survey was conducted between February and May 2023 in the Dar es Salaam Urban Cohort Study (DUCS) platform of the Ilala district in Dar es Salaam.""

Rationale: The paper describes a cross-sectional survey, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper mentions that most patients were receiving a DTG-based regimen, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper mentions that most patients were receiving a DTG-based regimen, which includes NRTIs and INSTIs.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""Approximately 99% were receiving tenofovir + lamivudine + dolutegravir as a fixed dose combination.""

Rationale: The paper mentions that most patients were receiving a DTG-based regimen, which includes tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, Lamivudine, Dolutegravir
""""""",105
38005921,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. Instead, it focuses on the development of a web service for predicting HIV drug resistance based on analysis of amino acid substitutions in main drug targets.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates. It mentions the use of sequences from the Stanford HIV Drug Resistance Database but does not list the accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not specify the number of individuals from whom samples were obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not specify the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not mention if the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not specify if the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not specify the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",57
38020274,"Here are the answers to the questions in the required format:

### Question 1: Does the paper report HIV sequences from patient samples?

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses genotypic resistance testing performed on patient samples to determine resistance mutations.

Rationale: The paper mentions that genotypic resistance testing was performed on patient samples, which indicates that HIV sequences from these samples were analyzed to determine resistance mutations.

Answer: Yes
""""""

### Question 2: Does the paper report in vitro drug susceptibility data?

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing.

Rationale: The paper focuses on clinical, virological, and pharmacokinetic analyses of patient samples experiencing virological failure during long-acting CAB/RPV therapy, but does not mention any in vitro drug susceptibility assays or data.

Answer: No
""""""

### Question 3: Were sequences from the paper made publicly available?

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, which indicates that the sequences were not made publicly available.

Answer: No
""""""

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

### Question 5: How many individuals had samples obtained for HIV sequencing?

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 311 APHI were included at the enrolment phase (T1).

Rationale: The paper states that 311 APHI were included at the enrolment phase (T1), which indicates that samples were obtained from these individuals for HIV sequencing.

Answer: 311
""""""

### Question 6: From which countries were the sequenced samples obtained?

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Cameroon.

Rationale: The paper states that the study was conducted in Cameroon, which indicates that the sequenced samples were obtained from this country.

Answer: Cameroon
""""""

### Question 7: From what years were the sequenced samples obtained?

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from 2018-2020.

Rationale: The paper states that the study was conducted from 2018-2020, which indicates that the sequenced samples were obtained during this time period.

Answer: 2018-2020
""""""

### Question 8: Were samples cloned prior to sequencing?

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing, which indicates that cloning was not performed.

Answer: No
""""""

### Question 9: Which HIV genes were reported to have been sequenced?

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic resistance testing was performed on the HIV-1 polymerase and reverse transcriptase gene regions.

Rationale: The paper states that genotypic resistance testing was performed on the HIV-1 polymerase and reverse transcriptase gene regions, which indicates that these genes were sequenced.

Answer: Polymerase, Reverse Transcriptase
""""""

### Question 10: What method was used for sequencing?

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the exact sequencing method used.

Rationale: The paper does not specify the exact sequencing method used, which indicates that the method is not reported.

Answer: Not reported
""""""

### Question 11: What type of samples were sequenced?

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that blood samples were used for sequencing.

Rationale: The paper states that blood samples were used for sequencing, which indicates that these samples were used.

Answer: Blood
""""""

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequencing was performed in participants experiencing VF.

Rationale: The paper states that sequencing was performed in participants experiencing VF, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

### Question 13: Were the patients in the study in a clinical trial?

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper does not mention that the patients were part of a clinical trial, which indicates that the study was not a clinical trial.

Answer: No
""""""

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the participants were on prolonged ART.

Rationale: The paper states that the participants were on prolonged ART, which indicates that the sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on RTI-based first-line ART and PI/r-based second-line ART.

Rationale: The paper states that the participants were on RTI-based first-line ART and PI/r-based second-line ART, which indicates that these drug classes were received by individuals in the study before sample sequencing.

Answer: RTI, PI/r
""""""

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the participants were on RTI-based first-line ART and PI/r-based second-line ART.

Rationale: The paper states that the participants were on RTI-based first-line ART and PI/r-based second-line ART, which indicates that these drugs were received by individuals in the study before sample sequencing.

Answer: RTI, PI/r
""""""",103
38022124,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention any HIV sequences from patient samples, as it does not report any sequencing data.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing or data related to the susceptibility of the virus to drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not report any individuals from whom samples were obtained for HIV sequencing, as it does not involve sequencing.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not specify the country or countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not specify the exact years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not discuss any cloning of samples prior to sequencing, as it does not report any sequencing data.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention any HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any sequencing methods, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not provide any information about the type of samples that were sequenced, as it does not report any sequencing data.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not report any sequences obtained from individuals with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: This retrospective analysis was performed in HIV-1-positive patients who were initiated BIC/FTC/TAF in the HIV clinic between June 2020 and June 2022.

Rationale: The paper describes a retrospective analysis rather than a clinical trial, indicating that the patients were not part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history, as it does not involve sequencing.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history, as it does not involve sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not report any HIV sequences from individuals, regardless of their previous ARV drug history, as it does not involve sequencing.

Answer: Not reported
""""""",61
38031075,"Here are the answers to the questions in the format you requested:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence.

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence.

Rationale: The paper does not mention the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence.

Rationale: The paper does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence.

Rationale: The paper does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence.

Rationale: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",54
38033131,"Here are the answers to the questions in the required format:

### Question 1: Does the paper report HIV sequences from patient samples?

Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence of HIV sequences from patient samples is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any HIV sequences from patient samples.

Answer: No

### Question 2: Does the paper report in vitro drug susceptibility data?

Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence of in vitro drug susceptibility data is reported in the provided text.

Rationale: The paper does not mention any in vitro drug susceptibility assays or data.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Question: Were sequences from the paper made publicly available?

Evidence: No evidence of publicly available sequences is reported in the provided text.

Rationale: The paper does not mention any publicly available sequences or provide any GenBank accession numbers.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No GenBank accession numbers are reported in the provided text.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence of HIV sequencing is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any number of individuals with samples obtained for HIV sequencing.

Answer: Not reported

### Question 6: From which countries were the sequenced samples obtained?

Question: From which countries were the sequenced samples obtained?

Evidence: No evidence of sequenced samples is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any country of origin for sequenced samples.

Answer: Not reported

### Question 7: From what years were the sequenced samples obtained?

Question: From what years were the sequenced samples obtained?

Evidence: No evidence of sequenced samples is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any years for sequenced samples.

Answer: Not reported

### Question 8: Were samples cloned prior to sequencing?

Question: Were samples cloned prior to sequencing?

Evidence: No evidence of cloning prior to sequencing is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any cloning prior to sequencing.

Answer: Not reported

### Question 9: Which HIV genes were reported to have been sequenced?

Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence of HIV sequencing is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any HIV genes that were sequenced.

Answer: Not reported

### Question 10: What method was used for sequencing?

Question: What method was used for sequencing?

Evidence: No evidence of sequencing method is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any sequencing method.

Answer: Not reported

### Question 11: What type of samples were sequenced?

Question: What type of samples were sequenced?

Evidence: No evidence of sample type is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any type of samples that were sequenced.

Answer: Not reported

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence of sequencing from individuals with virological failure is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any sequences from individuals with virological failure.

Answer: Not reported

### Question 13: Were the patients in the study in a clinical trial?

Question: Were the patients in the study in a clinical trial?

Evidence: The study was a retrospective follow-up study, not a clinical trial.

Rationale: The paper describes a retrospective follow-up study design and does not mention any clinical trial involvement.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence of HIV sequencing is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any sequences from individuals who had previously received ARV drugs.

Answer: Not reported

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence of drug classes is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any drug classes that were received by individuals before sample sequencing.

Answer: Not reported

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence of specific drugs is reported in the provided text.

Rationale: The paper does not mention any HIV sequencing or report any specific drugs that were received by individuals before sample sequencing.

Answer: Not reported",85
38058846,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance.

Rationale: The paper does not explicitly state that HIV sequences were obtained from patient samples, but it does describe the use of HIV drug resistance testing, which typically involves sequencing HIV genes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on clinical cases of dolutegravir resistance in pregnant and breastfeeding women and does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention making the sequences publicly available or providing GenBank accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes three cases of pregnant and breastfeeding women who developed dolutegravir resistance.

Rationale: The paper presents three cases of individuals from whom HIV sequencing was performed.

Answer: 3
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper describes cases of pregnant and breastfeeding women in South Africa.

Rationale: The paper specifically mentions that the cases were from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper describes cases of pregnant and breastfeeding women who developed dolutegravir resistance between 2020 and 2023.

Rationale: The paper provides a timeline indicating that samples were collected between 2020 and 2023.

Answer: 2020-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions HIV drug resistance testing, which typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Rationale: The paper does not explicitly state which HIV genes were sequenced, but it mentions HIV drug resistance testing, which typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the cases were pregnant and breastfeeding women, indicating that the samples were from plasma.

Rationale: The paper does not explicitly state the type of samples sequenced, but it mentions that the cases were pregnant and breastfeeding women, indicating that the samples were from plasma.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes cases of pregnant and breastfeeding women who developed dolutegravir resistance, indicating that they experienced virological failure on their treatment regimens.

Rationale: The paper describes cases of individuals who developed treatment-emergent resistance mutations, which means they experienced virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes case reports of patients treated at a clinic, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes cases of pregnant and breastfeeding women who developed dolutegravir resistance, indicating that they had previously received ARV drugs.

Rationale: The paper describes cases of individuals who had treatment-emergent resistance, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper lists various antiretroviral drugs from different classes that the patients received before the genotypic resistance tests.

Rationale: The paper lists specific antiretroviral drugs that the patients received before the samples were obtained for sequencing.

Answer: NRTI, NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper lists specific antiretroviral drugs that the patients received before the samples were obtained for sequencing.

Rationale: The paper lists specific antiretroviral drugs that the patients received before the samples were obtained for sequencing.

Answer: Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)
""""""",83
38072961,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses a case report involving a patient with HIV infection and describes the use of genotypic drug resistance testing by Sanger sequencing to identify emergent resistance mutations in plasma viral load specimens collected after combination antiretroviral therapy initiation.

Rationale: The paper focuses on a clinical case report and discusses the patient's history, treatment, and genotypic resistance data. It does not mention any in vitro drug susceptibility testing or results.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on a clinical case report and discusses the patient's history, treatment, and genotypic resistance data. It does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper does not report in vitro drug susceptibility data. Instead, it focuses on clinical cases of treatment-emergent resistance to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in HIV patients treated with bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC).

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case report involving a patient with HIV infection.

Rationale: The paper discusses a single case report involving a patient, indicating that only one individual's samples were sequenced.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the patient.

Rationale: The paper does not provide information about the country of origin for the patient.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient was diagnosed with HIV infection five years ago.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic drug resistance testing by Sanger sequencing was used to identify emergent resistance mutations in plasma viral load specimens collected after combination antiretroviral therapy initiation.

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that genotypic drug resistance testing by Sanger sequencing was used to identify emergent resistance mutations in plasma viral load specimens collected after combination antiretroviral therapy initiation.

Rationale: The paper specifies that Sanger sequencing was used for genotypic drug resistance testing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma viral load specimens were used for sequencing.

Rationale: The paper specifies that plasma viral load specimens were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a case of a patient who experienced virological failure on their treatment regimen.

Rationale: The paper discusses a patient who experienced virological failure, which indicates that sequences were obtained from an individual with virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patient was part of a clinical trial.

Rationale: The paper does not mention any clinical trial involvement.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes a case of a patient who had previously received antiretroviral therapy (ART).

Rationale: The paper discusses a patient who had previously received ART, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had previously received tenofovir, lamivudine, and efavirenz, and later switched to tenofovir, lamivudine, and lopinavir/ritonavir.

Rationale: The paper lists specific antiretroviral drugs that the patient received before sample sequencing, which belong to the NRTI, NNRTI, and PI classes.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient had previously received tenofovir, lamivudine, and efavirenz, and later switched to tenofovir, lamivudine, and lopinavir/ritonavir.

Rationale: The paper lists specific antiretroviral drugs that the patient received before sample sequencing.

Answer: Tenofovir, lamivudine, efavirenz, lopinavir/ritonavir
""""""",88
38090027,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the reporting of HIV sequences from patient samples.

Rationale: The paper focuses on the efficacy and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF) in clinical practice, and does not mention the reporting of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical outcomes and resistance mutations in patients, but does not mention any in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any information about making sequences publicly available.

Rationale: The paper does not mention whether the sequences were made publicly available, nor does it provide any relevant information to determine this.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide information about the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide information about cloning procedures.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information about sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide information about the patients being in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about the drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",71
38140553,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to drug resistance assays in a laboratory setting.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the identification of recombinant forms and drug resistance mutations, but does not mention any experiments or data related to in vitro drug susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that all nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.

Rationale: The paper explicitly mentions that the sequences were made publicly available in the Los Alamos laboratory database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper mentions that the sequences were deposited in the Los Alamos laboratory database, but does not provide the specific GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 sequences from 3178 patient samples.

Answer: 3178
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 sequences from patient samples obtained in Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts in the period 2011--2020.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 sequences from patient samples obtained between 2011 and 2020.

Answer: 2011-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper describes the use of Sanger sequencing for the HIV-1 pol region, but does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 pol sequences, which includes the protease (PR) and reverse transcriptase (RT) genes.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used for the HIV-1 pol region.

Rationale: The paper describes the use of Sanger sequencing for the HIV-1 pol region.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the study analyzed 3178 HIV-1 pol sequences obtained from HIV-infected patients from seven Russian federal districts.

Rationale: The paper clearly states that the study involved the analysis of HIV-1 sequences from patient samples, but does not specify the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention obtaining sequences from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the analysis of HIV-1 sequences from patient samples, but does not mention any information about virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the study as a molecular genetic monitoring of the HIV epidemic in Russia, but does not mention any clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that some patients were on combination antiretroviral therapy (cART), indicating that some sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper mentions that some patients were on cART, but does not provide specific information about the treatment history of all patients.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drug classes received by individuals before sample sequencing.

Rationale: The paper mentions that some patients were on cART, but does not provide specific information about the drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide specific information on the drugs received by individuals before sample sequencing.

Rationale: The paper mentions that some patients were on cART, but does not provide specific information about the drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",89
38140649,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that HIV-1 RNA plasma samples were collected from newly diagnosed HIV patients over a four-year period during the diagnostic process and clinical follow-up at UHID.

Rationale: The paper specifically focuses on the analysis of HIV-1 sequences from patient samples, indicating that the study involved sequencing HIV from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or data related to drug resistance assays in a laboratory setting.

Rationale: The paper focuses on the presence of drug resistance mutations rather than susceptibility, and there is no mention of in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly states that the sequences were made publicly available in the GeneBank nucleotide sequence database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that all sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875.

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates.

Answer: OR605755-OR606279, OR613869-OR613875
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that a total of 280 newly diagnosed treatment-naïve persons entered the Croatian Reference Centre for HIV-AIDS at UHID in the period 2019--2022, but 10 people did not meet the inclusion criteria.

Rationale: The paper states that the final data set consisted of 270 persons.

Answer: 270
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that most of the patients originated from and reported Croatia as the country of infection.

Rationale: The paper specifically states that the study was conducted in Croatia.

Answer: Croatia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from January 2019 to December 2022.

Rationale: The paper specifically states the time frame during which the samples were collected.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any process of cloning samples prior to sequencing.

Rationale: The paper describes the RNA extraction, amplification, and sequencing processes, but does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that amplification of the HIV-1 pol gene was performed for two regions in two separate reactions: (1) sequencing of the HIV-1 protease and partial sequencing of the reverse transcriptase gene; and (2) sequencing of the HIV-1 integrase gene.

Rationale: The paper specifically mentions the sequencing of the protease, reverse transcriptase, and integrase genes.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that population sequencing was performed with ABI Prism BigDye Terminator Cycle Sequencing kit and ABI 3730 XL sequencer.

Rationale: The paper specifically states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that viral RNA was isolated from plasma samples.

Rationale: The paper specifically states that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study focused on treatment-naive individuals, but some individuals were identified with SDRMs.

Rationale: The paper does not specifically state that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper describes the collection of samples from HIV-1-infected patients recruited from hospital, but does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper specifically focuses on treatment-naive individuals, meaning that the participants had not previously received antiretroviral drugs.

Rationale: The paper does not mention that the individuals had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper does not provide information on the drug classes received by individuals in the study before sample sequencing.

Answer: nan
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the individuals had previously received ARV drugs.

Rationale: The paper does not provide information on the drugs received by individuals in the study before sample sequencing.

Answer: nan
""""""",86
38140667,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

Evidence: ""We performed a retrospective review of treatment-experienced patients who started DTG + 3TC in a cohort of PWH. HIV-RNA <50 copies/mL was analysed at 144 weeks in an intention-to-treat (ITT) analysis (missing = failure) and a per-protocol (PP) analysis (patients with missing data or changes for reasons other than virological failure were excluded).""

Rationale: The paper mentions that HIV-RNA was analyzed, which means extracted from plasma, indicating that HIV sequences from patient samples were reported.

Answer: Yes

### Question 2: Does the paper report in vitro drug susceptibility data?

Evidence: ""No evidence""

Rationale: The paper does not mention any in vitro drug susceptibility testing or results.

Answer: No

### Question 3: Were sequences from the paper made publicly available?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""No evidence""

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

### Question 5: How many individuals had samples obtained for HIV sequencing?

Evidence: ""The study population comprised 358 PWH (19% women).""

Rationale: The paper mentions that the study population comprised 358 people with HIV (PWH), indicating that 358 individuals had samples obtained for HIV sequencing.

Answer: 358

### Question 6: From which countries were the sequenced samples obtained?

Evidence: ""We retrospectively reviewed all PWH under regular follow-up at our centre (Hospital Universitario La Paz, Madrid)...""

Rationale: The study was conducted at Hospital Universitario La Paz in Madrid, Spain, and the patient cohort was from this center.

Answer: Spain

### Question 7: From what years were the sequenced samples obtained?

Evidence: ""A search was conducted for all PWH prescribed DTG-2DR from 1 January 2015 to the date of data censor on 31 October 2021.""

Rationale: The study includes data from patients who were prescribed DTG-2DR from January 1, 2015, to October 31, 2021.

Answer: 2015-2021

### Question 8: Were samples cloned prior to sequencing?

Evidence: ""Historical protease, transcriptase, and integrase resistance mutations after a previous virolog- ical failure or before first ART initiation were collected. Resistance-associated mutations (RAMs) had been ana- lysed by Sanger sequencing of RNA. All patients had at least one resistance test performed.""

Rationale: The paper does not mention that samples were cloned prior to sequencing.

Answer: No

### Question 9: Which HIV genes were reported to have been sequenced?

Evidence: ""Historical protease, transcriptase, and integrase resistance mutations after a previous virolog- ical failure or before first ART initiation were collected.""

Rationale: The paper mentions that historical protease, transcriptase, and integrase resistance mutations were collected, indicating that these genes were sequenced.

Answer: PR, RT, IN

### Question 10: What method was used for sequencing?

Evidence: ""Resistance-associated mutations (RAMs) had been analysed by Sanger sequencing of RNA.""

Rationale: The paper explicitly states that resistance-associated mutations were analyzed by Sanger sequencing of RNA.

Answer: Sanger sequencing

### Question 11: What type of samples were sequenced?

Evidence: ""Resistance-associated mutations (RAMs) had been analysed by Sanger sequencing of RNA.""

Rationale: The paper mentions that HIV-RNA was analyzed, which means extracted from plasma.

Answer: Plasma

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: ""Previous virological failure was reported in 27.1% of patients, and the M184V resistance mutation was detected in 17 patients.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure.

Answer: Yes

### Question 13: Were the patients in the study in a clinical trial?

Evidence: ""Patients in clinical trials were excluded.""

Rationale: The paper explicitly states that patients in clinical trials were excluded from the study.

Answer: No

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: ""The study population comprised 358 PWH (19% women). Median age and time with HIV infection were 51.7 and 13.4 years, respectively. The median number of previous antiretroviral combinations was three.""

Rationale: The paper mentions that the study included treatment-experienced patients who started DTG + 3TC in a cohort of PWH, and the study population had median number of previous antiretroviral combinations was three.

Answer: Yes

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: ""Most of the patients (70.7%) switched from a previous combination that included two nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transcriptase inhibitor (INSTI) (63.7% DTG). Switches from two NRTIs plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) were recorded in 10.6% of patients; 6.7% of patients switched from another dual-therapy regimen with a boosted protease inhibitor plus 3TC.""

Rationale: The paper mentions that patients switched from combinations that included NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTI, NNRTI, PI, INSTI

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

Evidence: ""A total of 358 patients from the cohort switched from another ART combination to dual therapy with DTG + 3TC before August 2019. All patients started with the two drugs separated and were changed to the co-formulated DTG/3TC as of February 2020, which was when co-formulation was available in our centre.""

Rationale: The paper mentions all patients started with the two drugs separated and were changed to the co-formulated DTG/3TC.

Answer: Dolutegravir (DTG), Lamivudine (3TC)",103
38142692,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper discusses the use of HIV drug resistance genotyping to guide the selection of a suitable regimen and mentions that HIV drug resistance (DR) genotyping was performed.

Rationale: The paper mentions that HIV drug resistance genotyping was performed, which involves analyzing HIV sequences from patient samples to identify drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper focuses on clinical outcomes and genotypic resistance testing rather than in vitro susceptibility assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper includes 1214 participants in the study.

Rationale: The paper mentions that 1214 participants were included in the study.

Answer: 1214
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in South Africa.

Rationale: The paper specifically mentions that the study was conducted in South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from Dec 1, 2019, to Nov 30, 2020.

Rationale: The paper provides the timeline for the enrollment of participants.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention any cloning of samples prior to sequencing.

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that HIV drug resistance genotyping was performed, which typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Rationale: The paper mentions that HIV drug resistance genotyping was performed, which typically involves sequencing the reverse transcriptase, protease, and integrase genes.

Answer: RT, PR, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not specify the exact sequencing method used for genotypic resistance testing.

Rationale: The paper does not specify the sequencing method used for the genotypic resistance tests.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that viral load was routinely taken at 6 and 12 months after ART initiation and every 12 months thereafter, unless viraemia occurred.

Rationale: The paper mentions that viral load was measured, but doesn't mention the plasma were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study included people living with HIV who experienced virological failure on first-line NNRTI-based ART.

Rationale: The paper specifically focuses on people who experienced virological failure on first-line NNRTI-based ART.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper describes a retrospective cohort study with routine data from 59 ART clinics in South Africa.

Rationale: The paper is described as a retrospective cohort study, not a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included people living with HIV who experienced virological failure on first-line NNRTI-based ART.

Rationale: The paper includes people who experienced virological failure on first-line NNRTI-based ART, which means sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included people living with HIV who experienced virological failure on first-line NNRTI-based ART.

Rationale: The paper mentions that the study included people who experienced virological failure on first-line NNRTI-based ART, which means they had previously received NNRTI-based regimens.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included people living with HIV who experienced virological failure on first-line NNRTI-based ART.

Rationale: The paper mentions that the study included people who experienced virological failure on first-line NNRTI-based ART, which means they had previously received NNRTI-based regimens.

Answer: NNRTI-based regimens
""""""",81
38152686,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper describes the clinical case of an HIV/Tuberculosis coinfected patient who developed Human Immunodeficiency Virus (HIV) treatment failure during dolutegravir therapy.

Rationale: The paper discusses a case report involving a patient with HIV, and it mentions that genotyping was performed to identify drug resistance mutations, indicating that HIV sequences from patient samples were analyzed.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper focuses on a clinical case report and discusses the patient's history, treatment, and genotypic resistance data. It does not mention any in vitro drug susceptibility testing or results.

Rationale: The paper does not provide any specific in vitro drug susceptibility data. It focuses on the clinical case and the emergence of resistance mutations in the context of treatment.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not mention whether the sequences obtained were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper describes a single case report of a 29-year-old male patient.

Rationale: The focus of the paper is on one individual, indicating that only one person had samples obtained for sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not mention any specific countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient was admitted in 2019 and returned to the outpatient clinic after 7 months.

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention any cloning of samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotyping was performed to identify drug resistance mutations in the integrase gene.

Rationale: The paper specifically mentions the sequencing of the integrase gene to identify drug resistance mutations.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not specify the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that the patient had a viral load of 437,927 cp/mL, indicating that plasma samples were analyzed.

Rationale: The paper specifies that plasma samples were analyzed, indicating that this was the clinical specimen type used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper describes a patient who experienced virological failure on a treatment regimen.

Rationale: The paper discusses a patient who had virological failure on a treatment regimen, and sequences were obtained from this individual.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not mention that the patient was part of a clinical trial. The study is a case report.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper describes a patient who was on antiretroviral therapy (ART) and experienced virological failure.

Rationale: The paper discusses a patient who had previously received ARV drugs and had virological failure, indicating that sequences were from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was on a regimen of Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG).

Rationale: The paper lists specific antiretroviral drugs that the patient received before the samples were obtained for sequencing, including NRTI (TDF, 3TC) and INSTI (DTG).

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient was on a regimen of Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG).

Rationale: The paper lists specific antiretroviral drugs that the patient received before the samples were obtained for sequencing, including Tenofovir (TDF), Lamivudine (3TC), and Dolutegravir (DTG).

Answer: Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)
""""""",80
38314093,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention the analysis of HIV sequences from patient samples. However, it discusses the analysis of serum samples from HIV-infected individuals and the detection of HIV antibodies using Western blotting.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not explicitly mention the analysis of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility testing or data.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention in vitro drug susceptibility testing or data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates, indicating that the sequences were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention any process of cloning samples prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were part of a clinical trial.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention that the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper focuses on the epidemiological and clinical features of HIV-infected individuals in Meizhou, China, and does not mention the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",87
38427738,"""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention the use of patient samples for obtaining HIV sequences. It focuses on laboratory-based studies and does not mention the submission of sequences to GenBank.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: No evidence

Rationale: The paper does not mention in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: No evidence

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not provide information on whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not provide information on whether the individuals in the study had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the drug classes that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide information on the specific drugs that were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",63
38864613,"Here are the answers to the questions in the format you requested:

### Question 1: Does the paper report HIV sequences from patient samples?

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: No evidence

Rationale: The paper does not mention any patient samples or sequences derived from patients. It primarily discusses in vitro studies and resistance mechanisms.

Answer: No
""""""

### Question 2: Does the paper report in vitro drug susceptibility data?

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: ""ISL and LEN were evaluated for their ability to prevent HIV-1 infection in MT4-GFP cells as described in Diamond et al. ( 6 ). In this method, HIV-1 replication is monitored using MT4-gag-GFP clone D3, MT4 cells with a GFP reporter gene, the expression of which is dependent on the HIV-1 expressed proteins, Tat and Rev ( 13 ).""

Rationale: The paper includes in vitro drug susceptibility data, specifically examining the susceptibility of HIV-1 to ISL and LEN using MT4-GFP cells.

Answer: Yes
""""""

### Question 3: Were sequences from the paper made publicly available?

""""""
Question: Were sequences from the paper made publicly available?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper mentions that sequences from resistance selection experiments have been deposited in GenBank.

Answer: Yes
""""""

### Question 4: What were the GenBank accession numbers for sequenced HIV isolates?

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: ""Sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.""

Rationale: The paper mentions that sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.

Answer: PP827803 -- PP828572
""""""

### Question 5: How many individuals had samples obtained for HIV sequencing?

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: No evidence

Rationale: The paper does not mention any individuals or samples obtained for sequencing, as it primarily discusses in vitro studies.

Answer: Not reported
""""""

### Question 6: From which countries were the sequenced samples obtained?

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide any information regarding the geographical origin of the samples, as it primarily focuses on in vitro studies.

Answer: Not reported
""""""

### Question 7: From what years were the sequenced samples obtained?

""""""
Question: From what years were the sequenced samples obtained?

Evidence: No evidence

Rationale: The paper does not provide specific years for when the sequenced samples were obtained.

Answer: Not reported
""""""

### Question 8: Were samples cloned prior to sequencing?

""""""
Question: Were samples cloned prior to sequencing?

Evidence: No evidence

Rationale: The paper does not mention the sequencing method used, nor samples were cloned prior to sequencing.

Answer: Not reported
""""""

### Question 9: Which HIV genes were reported to have been sequenced?

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: ""The CA or RT-encoding region was amplified by the one-step RT-PCR method. PCR products were genotyped by an automated population-based full-length sequencing method (covering amino acids 1--231 of the CA region and 1--440 of the RT region).""

Rationale: The paper mentions that the CA and RT regions were sequenced.

Answer: CA, RT
""""""

### Question 10: What method was used for sequencing?

""""""
Question: What method was used for sequencing?

Evidence: ""The CA or RT-encoding region was amplified by the one-step RT-PCR method. PCR products were genotyped by an automated population-based full-length sequencing method (covering amino acids 1--231 of the CA region and 1--440 of the RT region).""

Rationale: The paper mentions that a one-step RT-PCR method was used for amplification, followed by an automated population-based full-length sequencing method.

Answer: RT-PCR and automated population-based full-length sequencing
""""""

### Question 11: What type of samples were sequenced?

""""""
Question: What type of samples were sequenced?

Evidence: No evidence

Rationale: The paper does not mention any clinical specimens being sequenced, as it focuses on in vitro studies and resistance mechanisms.

Answer: Not reported
""""""

### Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: No evidence

Rationale: The paper does not discuss any patient samples or sequences related to virological failure, focusing instead on laboratory studies.

Answer: No
""""""

### Question 13: Were the patients in the study in a clinical trial?

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: No evidence

Rationale: The paper does not provide any information regarding clinical trials involving patients, as it focuses on laboratory studies.

Answer: No
""""""

### Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: No evidence

Rationale: The paper does not mention any sequences from individuals who had received antiretroviral drugs, focusing instead on laboratory studies.

Answer: No
""""""

### Question 15: Which drug classes were received by individuals in the study before sample sequencing?

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not provide any information regarding drug classes received by individuals, as it does not discuss patient samples.

Answer: Not reported
""""""

### Question 16: Which drugs were received by individuals in the study before sample sequencing?

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: No evidence

Rationale: The paper does not mention any specific drugs received by individuals, as it focuses on in vitro studies and resistance mechanisms.

Answer: Not reported
""""""",98
